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ABSTRACT
Author: Kole, Ayeeshik PhD
Institution: Purdue University
Degree Received: May 2018
Title: Depth-Resolved Assessment of Atherosclerosis by Intravascular PhotoacousticUltrasound Imaging
Major Professors: Michael Sturek, Ji-Xin Cheng
Coronary heart disease is the leading cause of death in the United States and the
incidence is projected to increase by 18% by 2030. Yet, there remains a pressing clinical
need for tools to detect vulnerable atherosclerotic plaques that can rupture and lead to major
adverse cardiac events. Plaques that are considered most vulnerable for rupture are thincapped fibroatheromas, which are grossly defined by hallmarks of a thin fibrous cap, a
large lipid-rich necrotic core, inflammatory infiltrate, and positive remodeling. These
plaques are often structurally non-obstructive to moderately obstructive, thus
asymptomatic and clinically unidentifiable with routine angiography and stress testing.
Rather, their vulnerability is a product of their chemical composition.
We have developed a dual-mode intravascular catheter which is capable of producing
co-registered cross-sectional images of arterial wall morphology and lipid content, via
ultrasound and photoacoustic modes, respectively. Validation of this capability will rely
on interrogation of atherosclerotic coronary arteries from humans and peripheral arteries
from swine, with comparison to gold-standard histopathology and competing technologies.
Here, we present ex vivo validation of a novel intravascular photoacoustic-ultrasound
(IVPA-US) imaging catheter and the first systematic in vivo IVPA-US imaging study in a
preclinical swine model with native disease, necessary benchmarks before proceeding with
translation to clinic. We aim to ultimately demonstrate predictive utility to detect plaques
that are vulnerable to rupture and trigger adverse cardiac events. In addition, this will be
instrumental in elucidating the mechanism of plaque rupture, the development of
preventive and therapeutic interventions, and reducing coronary heart disease-related
mortality.
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1. INTRODUCTION
Atherosclerosis Definitions, Epidemiology, and Significance
Atherosclerosis is a chronic pathology of large- and medium-sized arteries, in which
lipids, fibrous elements, and cellular debris progressively accumulate in the inner arterial
wall forming a waxy substance termed a plaque [1, 2]. When atheromatous plaques build
in the coronary arterial tree of the heart, the pathology is referred to as coronary artery
disease (CAD), which continues to be the number one cause of death for men and women
in the United States (Fig. 1.1) [3-5]. Plaques in the coronary artery can cause disease by
encroaching upon the vessel lumen as they grow in size. Eventually, this narrowing or
stenosis becomes severe enough to clinically present as chest pain upon exertion, or stable
angina. The plaque can also suddenly rupture, exposing the pro-coagulant material within
the plaque core to the coagulation proteins present in the blood stream, which triggers clot
formation, or thrombosis [1, 6-8]. The resulting thrombus can lodge in a coronary artery
and impede blood flow, causing acute coronary syndrome (ACS), which is an umbrella
term for unstable angina and myocardial infarction. During a myocardial infarction,
commonly known as a heart attack, lack of blood flow through the coronary arteries starves
cardiac muscle of oxygen (ischemia), creating an infarct where the myocardium has been
irreversibly damaged [6].
The American Heart Association estimates that the direct and indirect national costs of
CAD are upward of $200 billion and that approximately every 44 seconds, an American
will suffer from a myocardial infarction [3]. While research and advancements into the
pathogenesis, diagnosis, surveillance, and treatment of coronary atherosclerosis has been
prolific in the last two decades, immense challenges remain as CAD incidence is projected
to increase by 18% in the next fifteen years [3-5].
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Figure 1.1. Coronary artery disease death rate in the United States. Map of the contiguous United States,
showing the coronary artery disease death rate per 100,000 for all adults between 2013 and 2015. This map
was created using the Interactive Atlas of Heart and Disease and Stroke, a website developed for the Centers
for Disease Control and Prevention, Division of Heart Disease and Stroke Prevention.
http://nccd.cdc.gov/DHDSPAtlas.

Atherosclerosis Pathogenesis
To achieve scientific progress towards combatting atherosclerosis, it is imperative to
understand the etiology of the disease, which has only recently been realized to have a
complex pathophysiology that is more involved than simple storage of excess lipids [2, 712]. The contemporary schema presents atherogenesis as a chronic inflammatory “response
to injury” which begins with an insult to the endothelial cell layer that lines the inner most
tunica intima of the artery [1, 2, 12]. Injury or dysfunction of the endothelium permits the
entry and retention of lipids such as low-density lipoprotein (LDL) particles within the
artery wall. Simultaneously, the activated endothelial layer also promotes adhesion of
blood leukocytes, the most abundant of which are monocytes. Monocytes migrate into the
intima and undergo maturation into tissue macrophages, which take up retained lipids
intracellularly, becoming foam cells. An early stage lesion begins as a fatty streak, a flat
yellow lesion of the intima present in most adolescents [1, 13]. With increasing age, a
streak matures into a more complicated plaque with a significant lipid core that can
potentially limit blood flow. A key process in the evolution of a streak to an advanced
lesion is the migration and proliferation of smooth muscle cells (SMCs) from the tunica
media (the middle layer of the artery) to the intima. This occurs primarily in response to
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mediators such as platelet-derived growth factor, released by local platelets present to heal
vascular injury. Along with intimal proliferation, media-derived SMCs also synthesize and
deposit extracellular matrix components contributing to a fibrous cap over the plaque.
Many of the lipid-laden macrophages die and release extracellular lipids [1, 10, 11, 14]. A
combination of cellular debris and lipids constitute a lipid-rich necrotic core, which is
particularly thrombogenic if the fibrous cap covering the plaque ruptures, ulcerates, or
erodes (Fig. 1.2) [1, 6, 11, 15, 16].

Figure 1.2. Pathophysiology of atherosclerosis. A) Normal artery anatomy with three layers: tunica intima,
tunica media, and tunica adventitia. B) Activated endothelium recruits inflammatory monocytes that migrate
into the intima. After maturation to macrophages and lipid uptake, they become foam cells. C) Migration and
proliferation of smooth muscle cells (SMCs) from the media to the intima. There is also increased
extracellular matrix deposition. In advancing lesions, SMCs and macrophages die by apoptosis, leaving
behind necrotic debris intermixed with lipid. D) Rupture of the fibrous cap presents the pro-coagulant plaque
material to blood, triggering thrombus formation and the obstruction of blood flow. Adapted from Libby et
al. (Nature, 2011).
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Thin-Capped Fibroatheromas and the “Vulnerable” Plaque Hypothesis
The susceptibility of a plaque to rupture and subsequently trigger ACS is defined as its
vulnerability [17, 18]. While a previous American Heart Association classification
delineated atherosclerotic lesions into six classes: three pre-atheromatous (types I-III) and
three atheromatous (types I-IV), this scheme has been criticized for its implication of a
linear, orderly progression of lesion type [19, 20]. With new morphometric data from
autopsy specimens, the classification scheme has been revised into seven morphological
categories that better illustrate our current understanding of atherosclerosis: intimal
thickening, intimal xanthoma (fatty streak), pathologic intimal thickening, fibrous cap
atheroma, thin-cap fibrous atheroma (TCFA), calcified nodule, and fibrocalcific plaque
(Fig. 1.3) [21-23].

Figure 1.3. Simplified scheme for classifying atherosclerotic lesions based on morphology. The
classification scheme has been modified from the current American Heart Association recommendations,
with the seven major subtypes depicted in light orange boxes. This scheme better illustrates the non-linear
progression between subtypes, and advancement to plaque events (erosion, healing, and thrombosis) and
major adverse cardiovascular events, such as acute coronary syndrome. The thickness of lines indicate the
estimated frequency of each pathway. Adapted from Yahagi et al. (Nat Rev Cardiol, 2016).

A fracture of the thin, collagen-poor cap of a TCFA makes this plaque morphology type
the most common precursor to an atherothrombotic event, and consequently the most
common vulnerable plaque [15, 16, 18, 21, 22, 24-28]. In addition, these rupture- and
thrombosis-prone plaques are often positively remodeled and non-obstructive, thus
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evading detection on routine stress testing and coronary angiography [26]. Positive
remodeling is a compensatory enlargement of the media and external elastic membrane
(EEM) of an artery during atherogenesis [29, 30]. As a result, plaques can increase in size
without reducing luminal area, and is a phenomenon characteristic of unstable, vulnerable
plaques [29, 31].
There is currently no diagnostic test routinely used in practice to reliably identify TCFA,
despite the pressing clinical need. Identification of vulnerable plaques before rupture will
be instrumental in fully realizing the mechanisms underlying lesion progression to ACS,
the future development of preventative and therapeutic interventions, and reducing CADrelated morbidity and mortality. Catheter-based imaging modalities may hold the answer,
as they continue to advance technology necessary to detect pathologic hallmarks of TCFA,
such as a thin fibrous cap, large lipid-rich necrotic core, inflammatory infiltrate, and
positive remodeling (Fig. 1.4) [32].
A more detailed definition recognizes the most important histological marker of a true
TCFA as a sufficiently thin cap (<65 μm). This threshold has been determined from human
autopsy studies of 41 ruptured plaques, in which 95% of fibrous caps measured less than
64 μm [22, 33, 34]. In addition, mechanical studies have shown that circumferential stress
increases exponentially as cap thickness decreases [24, 35]. Moreover, this cap
demonstrates dense inflammatory infiltration, with >25 macrophages per highmagnification field (0.3 mm diameter field) [33]. The prevailing hypothesis proposes that
inflammatory cells and subsequent cytokines drive the production of proteases (e.g.
collagenase, gelatinases, stromolysin, and cathepsins), thus weakening an already thin cap
via extracellular matrix breakdown [2, 22, 24, 36-39].
Another key feature is a large lipid-rich necrotic core, which was commonly
hypothesized as a core composing ≥40-50% of plaque area [40, 41]. However, more recent
studies have found evidence of a smaller necrotic core (23 ± 17%) in unruptured TCFAs
and slightly larger in plaque ruptures (34 ± 17%) [22, 41]. Although the necrotic core of a
TCFA is lipid-rich, it is distinct from a lipid pool, which is considered a more nascent
lesion. A necrotic core characteristically displays cellular debris of apoptotic cells and
cholesterol clefts, whereas a lipid pool is collection of lipids within a proteoglycan-rich
matrix [42].
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Figure 1.4. Thin-capped fibroatheroma hallmarks. A) Schematic of a TCFA showing a patent lumen and
a lipid-rich necrotic core with cholesterol clefts covered a thin fibrous cap with inflammatory infiltrate. B)
Histopathology of a TCFA showing the thin fibrous cap (FC) and necrotic core (NC). C) Gross image of a
TCFA with a hemorrhaged necrotic core (NC) and a thin fibrous cap shown between the arrows. Adapted
from Yahagi et al. (Nat Rev Cardiol, 2016), Virmani et al. (Arterioscler Thromb Vasc Biol, 2000), Narula et
al. (J Am Coll Cardiol, 2013).

Furthermore, studies have shown that an increased free-to-esterified cholesterol ratio
within the core promotes plaque rupture [43]. The core also contains increased tissue factor,
contributing to its thrombogenic potential [44].
Lastly, due to aforementioned positive remodeling, the majority of TCFAs produce <75%
area stenosis, which may render the lesion clinically asymptomatic [25, 45-49]. Another
relatively less-established finding of TCFA composition is neovascularization of the
plaque from the tunica adventitia (the outermost vessel layer). This has been hypothesized
to be an early defensive pathway to protect against hypoxia in a thickening plaque and also
promote lipid removal. However, in advanced lesions, it also permits increased leukocyte
influx to the plaque and inflammatory plaque destabilization [24, 50, 51]. Experimental
evidence has shown increased vasa vasorum microvessel density and expression of
endothelial adhesion molecules (e.g. ICAM-1, VCAM-1, E-selectin, and CD40) in lipidrich plaques [52].
Thus, definitive classification of a plaque as a TCFA requires identification of these key
histomorphic features. Furthermore, it must be done with ample sensitivity and specificity
to provide predictive utility in the clinic [53]. Intravascular imaging via catheter probes
offer the best opportunity to address this gap. It is likely this will necessitate a multi-mode
imaging tool, as no single modality is currently powerful enough to identify all hallmarks
of a TCFA: a thin-fibrous cap with inflammatory infiltrate, large lipid-rich necrotic core,
and positive remodeling [54-61].
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Overview of the Current Coronary Imaging Landscape
The following overview outlines the current status of intravascular coronary imaging
modalities and, by extension, hybrid modalities. For each modality, the history and
background, current status, advantages and shortcomings (in the context of TCFA detection)
will be presented (Table 1.1). All presented modalities are commercially available, except
the intravascular photoacoustic (IVPA) imaging catheters, of which the development and
validation is the focus of this dissertation. To narrow the scope, other promising
technologies are not discussed due to their limited body of current evidence. This includes
near-infrared fluorescence imaging [62-65], near-infrared autofluorescence imaging [66,
67], and fluorescence lifetime imaging [68-71].
1.4.1

Coronary X-ray Angiography

For over 50 years, coronary X-ray angiography has been a predominant diagnostic
imaging technique for identifying coronary anatomy and obstructive disease [72]. A trained
cardiologist inserts a flexible catheter through the femoral or brachial artery and threads it
into the coronary arteries of the heart (cardiac catheterization), where they inject iodinecontaining contrast dye. The cardiologist then uses steady beams of X-ray (fluoroscopy) to
produce a real-time image of the entire coronary arterial tree, or an angiogram, with a
spatial resolution of 130 to 200 μm (Fig. 1.5) [73]. The value in seeing coronary arteries
has revolutionized cardiovascular medicine and been the gold standard in assessing disease
severity and guiding revascularization decisions, although this status has recently been
fading. While certainly at no risk of being replaced, there is a strong push for angiography
to be supplemented with additional imaging modalities [74, 75].
Angiography has lost its luster due its limited capabilities [76-79]. Angiograms are only
able to display two-dimensional, planar silhouettes of the vessel lumen. As a result,
angiography has little diagnostic power in identifying plaques without functionally
significant stenosis, such as positively remodeled plaques [76]. Compensatory positive
remodeling is characteristic of vulnerable plaques and aids reasoning for the observed
discordance between reduced lumen diameter and progression to ACS [31, 48, 78, 80, 81].
Evidence from the late 1980s shows that in 66% of patients who presented with acute MI,
the occlusion occurred in areas that were previously normal on angiogram. Additionally,
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only 3% of acute MI patients had a previous high-grade stenosis on angiogram at the site
of occlusion [82]. This observation has driven further research and yielded the consensus
that non-obstructive lesions are a common source for ACS and vulnerability is a product
of plaque composition [18, 40, 41]. Angiography lacks the ability to provide information
about the arterial wall, and consequently, the ability to assess TCFA determinants: thin cap
with inflammatory infiltrate, lipid-rich necrotic core, and positive remodeling. Thus, while
angiography will continue as a valuable mainstay in cardiology, its limitations have
ushered in a wealth of new intravascular imaging modalities that can better detect
vulnerable plaques [54, 74, 76, 77, 83].

Figure 1.5. Coronary angiogram. Angiogram from an 85-year old male with history of coronary artery
disease. Arrows indicate areas of significant obstruction of the left anterior descending artery, immediately
distal to the first diagonal artery.

1.4.2

Grayscale Intravascular Ultrasound

The first ultrasound (US) images from within a human coronary artery were captured
by Paul Yock and colleagues in 1988 using a miniaturized single transducer system [84].
Since then, intravascular ultrasound (IVUS) has served as the most prominent catheterbased imaging device in the cardiac catheterization lab. It is commonly used to supplement
angiography for assessment of stenosis severity and guide percutaneous coronary
intervention. In the last two decades, the role of IVUS in the catheterization lab has
expanded to include optimization of stent implantation and prediction of complications
[85-88]. Furthermore, IVUS has played a pivotal role in research and influenced current
clinical guidelines and our understanding of atherosclerosis natural history via serial
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progression/regression studies [74, 76, 87-103]. While its versatility is undisputable, the
scope of this section will focus on its ability (or lack of ability) to delineate vulnerable
plaque, in regards to morphology and especially composition.
To appreciate the strengths and limitations of IVUS in characterizing plaque, it is
essential to understand the technology underlying image formation and basics of the
procedure. A typical IVUS imaging device consists of three main components: the catheter
(typical diameter: 1 mm) with an US transducer at its tip, a motorized pullback console,
and a wired signal processing system that displays visual output. US transducers generate
acoustic waves proportional to the voltage applied to a piezoelectric (pressure-electric)
material, via expansion and contraction of the material. The typical IVUS transducer
frequency is within the range of 20-60 MHz and is transmitted perpendicular to its axis.
After encountering tissue, a percentage of the emitted wave returns to the piezoelectric
material and imparts mechanical pressure, which is converted to an electrical signal that is
amplified, filtered, and reconstructed. The variation in signal intensity received (i.e.
backscattered, reflected) provides information on how much the emitted signal was
attenuated, and therefore tissue density and type. In addition, with temporal delay between
signal emission and reception, tissue position is recovered. This information is displayed
together as various shades on a gray scale. The length of a vessel can be imaged via cardiac
catheterization of the IVUS catheter to the distal end of a coronary artery and motorized
pullback (0.5-1 mm/s) of the catheter—or transducer within a catheter sheath—towards the
proximal ostium [85, 86, 104-107].
There are two different types of IVUS transducers, both of which are able to reconstruct
a real-time 360o cross-sectional topography of the vessel wall (Fig. 1.6A). Rotation (or
mechanical) IVUS catheters are composed of one piezoelectric transducer that rotates up
to 1,800 rotations/minute via flexible, high-torque drive shaft that extends the length of the
catheter to the motorized pullback console. The single transducer element sits
perpendicular to the catheter and scans the vessel cross-section as it spins within an
echolucent sheath, protecting the endothelium from damage during pullback. Commercial
rotational IVUS catheters all operate approximately at a center frequency of 40 to 50 MHz
with a small bandwidth. As a result of these higher transducer frequencies, mechanical
systems have the advantage of superior axial resolution (100-120 μm). The trade-off,
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however, comes from frequency-dependent attenuation that limits tissue penetration depth
to approximately 5 mm. This is still ample depth for assessment of positive remodeling.
Newer transducer technology expands depth resolution up to 16 mm with an extended
bandwidth that includes frequencies between 30 and 70 MHz [58, 108-110].
In contrast, an electronic phased-array catheter has multiple piezoelectric transducer
elements arranged circularly around the catheter tip. This solid-state design scans the vessel
cross-section with circumferential activation of the imaging elements via an embedded
microchip proximal to the transducer. Electronic signals are then transmitted by
microcables to the processing system where imaged sectors are reconstructed. The
processing time for reconstruction and the lower frequency at which phased-array catheters
operate give this design the disadvantage of lower temporal and axial resolution (150-250
μm), but the advantage of a higher tissue penetration depth [111]. The catheter itself retreats
during pullback, as the solid-state design does not necessitate a sheath. Commercial
phased-array IVUS catheters typically contain 64 elements and operate at 20 MHz [74, 83,
85, 86, 104-107, 112, 113].
Despite variations in transducer design, IVUS image interpretation of the crosssectional vessel topography is unchanged. Normal US appearance of a coronary artery
roughly mimics histology with the presence of three layers: intima, media, adventitia [114116]. Each of the layers vary in their ability to reflect acoustic signal. The intima is
relatively echogenic given the drastic change in acoustic impedance at the lumen-intima
border. The muscular media layer is homogenously composed of SMCs and echolucent, as
US transverses the layer without much reflection. Lastly, the adventitia is strongly
echogenic, a property of the abrupt change in impedance at the media-EEM border.
Together, the bright echoes of the intima and adventitia separated by a dark media is
classically described as the “three-layered” IVUS appearance of a coronary artery (Fig.
1.6B-D) [74, 85, 86, 104, 105, 117]. However, there are deviations to the three-layer
appearance, particularly in young patients with an intimal layer too thin to be resolved with
IVUS [118]. Thus, the IVUS image appears as a monolayer, composed solely of the
echogenic adventitia. Though, in most patients requiring cardiac catheterization, there is
sufficient and diffuse intimal thickening to appear on imaging and distinguish the three
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layers [85, 86, 105]. It is controversial whether this trilaminar appearance is truly normal
or a sign of early atherosclerosis [119, 120].

Figure 1.6. IVUS catheter schematics and image interpretation. A) Schematic of rotational and phasedarray IVUS catheter probe tips. In rotational catheters, a single transducer elements rotates to image the vessel
wall. In phased-array catheters, a series of transducers are sequentially activated to image the vessel wall. B,
C) IVUS image showing a healthy “three-layer” appearance of the intima (I), echolucent media (M), and
adventitia (A). D) Corresponding histology showing the same three layers. E) Echogenic calcification with
the arc of “acoustic shadowing” peripheral to the deposit outlined. F, G) Plaque (blue) detected by IVUS,
with lipid (green) identified by its echolucent nature. Panel A adapted from Kume et al. (Cardiology: An
Illustrated Textbook, 2012).

IVUS has strong evidence showing that it is a valuable modality in detecting
atheromatous plaque composition. It has high specificity and sensitivity for detection of
coronary artery calcification [121-124]. The signature of calcium deposits are their ability
to prevent US penetration, creating an “acoustic shadow” peripheral to the deposit (Fig.
1.6E). Calcification, while important in other plaque subtypes (calcific nodule, fibrocalcific
plaque), is not a major component of our lesion of interest: TCFAs [21]. IVUS has high
sensitivity (78-95%) for the detection of lipid pools that show up as echolucent (Fig.
1.6F,G). Specificity, though, is poor (30%) and cannot reliably differentiate between other
echolucent zones produced from loose tissue, shadowing, or plaque rupture [54, 83, 86,
125, 126]. In addition, the hallmark of a TCFA is lipid-rich necrotic core, meaning it is
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present with cellular debris that would reflect US differently than a uniform pool [127]. In
general, a lipid-laden lesion that has not yet ruptured will present with an echogenic fibrous
cap. However, as discussed before, the resolution of IVUS cannot distinguish features <100
μm and delineate the characteristic thin cap of a TCFA. This obstacle is unlikely to be
overcome because at transducer frequencies above 45 MHz, the US reflection from
aggregate blood cells—blood speckle—distorts a clean lumen-tissue interface [74, 104,
128]. Lastly, microbubble contrast-enhanced IVUS can identify vaso vasorum as a
surrogate marker of plaque inflammation, but is not widely verified [129, 130].
Despite the highlighted limitations in detection of TCFA characteristics, IVUS has great
clinical predictive value. The Providing Regional Observations to Study Predictors of
Events in the Coronary Tree (PROSPECT) trial was a multicenter natural history study of
atherosclerosis using intravascular imaging to prospectively identify vulnerable plaque in
697 patients. PROSPECT showed that plaque burden >70% and minimal lumen area <4
mm2, as determined by grayscale IVUS, were independent predictors of future major
adverse cardiovascular events (MACE) within 3.4 years at nonculprit (obstructive lesions
remote from the area of infarction) lesion sites (p<0.0001, HR=7.9, 5.0, respectively) [100].
Plaque burden refers to the area within the EEM occupied by atheroma and does not
necessarily correlate with stenosis, especially in the setting of positive remodeling [131].
These results provide strong evidence that a large plaque burden and/or small minimal
lumen area, as measured by grayscale IVUS, should be considered alongside traditional
TCFA hallmarks in future investigations. Furthermore, the few limitations of grayscale
IVUS in identifying these hallmarks can potentially be improved by sophisticated
radiofrequency (RF) analysis of the reflected US beam, also known as Virtual Histology
(VH)-IVUS.
1.4.3

Virtual Histology-Intravascular Ultrasound

IVUS grayscale images are formed by measuring the amplitude of the reflected US
signal wave, discarding other spectral parameters. RF analysis profits by extracting the
loads of discarded spectral information, using it to differentiate four plaque components—
fibrous, fibrofatty, necrotic, calcific—that were previously undistinguishable based on
amplitude alone [54, 85, 86, 105, 132]. In 2002, Anuja Nair and colleagues were first to
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show RF analysis using eight spectral parameters of the reflected signal could be used to
discern tissue components with sufficient predictive accuracy, as validated from 51 fresh,
post-mortem left anterior descending arteries compared to histopathology [133, 134]. This
validation study was repeated using a commercial 20 MHz phased-array catheter and an
algorithm trained to color map tissue components based on their spectral signatures (Fig.
1.7) [135]. Fibrous tissue (dark green), fibrofatty (light green), necrotic core (red), and
calcium (white) were identified with predictive accuracies of 93.5%, 94.1%, 95.8%, and
96.7%, respectively. This led to the first commercially available RF-analysis IVUS system:
Virtual Histology® IVUS (Volcano Corp.).

Figure 1.7. Virtual Histology-IVUS colorized classification. A) Grayscale IVUS image of an
atherosclerotic plaque. B) Colorization of four different plaque components by VH-IVUS algorithm based
on RF-analysis. Adapted from Muramatsu et al. (J Cardiol, 2015).

VH-IVUS has also been successfully validated in vivo, as there is strong correlation
between in vivo VH-IVUS measures and in vitro histopathology of the same plaques
obtained by atherectomy. Predictive accuracy ranged from 87.1% to 96.5% [136]. These
studies and many others have shown validity and reproducibility of VH-IVUS as a
diagnostic technology, thus renewing the outlook of IVUS in TCFA detection [137-141].
The next logical step from identifying individual plaque components is to use this
information to classify plaques based on phenotype. However, despite the improvements
of VH-IVUS, it is still limited by insufficient resolution to detect a thin fibrous cap [142].
Thus, investigators have formally defined what is known as a VH-TCFA (or IVUS-derived
TCFA), based on ex vivo histological analysis. A VH-TCFA is a lesion that, on at least
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three consecutive frames, contains a necrotic core ≥10% without an overlying fibrous cap
and a total plaque burden ≥40% [143]. This deviation from the histological definition is
problematic, particularly because it promotes a false assumption that absence of a
detectable cap means it is thin [89, 144]. In reality, this means the cap is below resolution
limits (<150-250 μm) and the lesion cannot be definitively classified as thin-capped versus
thick-capped. The notion that VH-TCFA is a reliable inference of true histological TCFA
has received further criticism. Many experts have questioned whether VH-IVUS can
accurately distinguish lipid pool from necrotic core, as they may overlap [32, 127, 145].
Additionally, others have highlighted that RF signal properties can be altered by factors
other than tissue property. For example, it has been shown that VH-IVUS misidentifies
stent struts as calcium surrounded by necrotic core [146].
Furthermore, Granada et al. produced evidence in a swine model of poor correlation
between plaque components identified by VH-IVUS and those identified by gold-standard
histopathology [147]. More recently, Thim et al. demonstrated that the necrotic cores as
identified by VH-IVUS were grossly misclassified as compared to histopathology in 18
lesions in an atherosclerotic minipig model [148]. In both instances, the results were met
with harsh criticism from experts in the field [149, 150]. Primarily, they cite that swine
atherosclerosis is not an accurate representation of complex human coronary plaques and
that necrotic cores differ in composition. Thus, it is irresponsible to expect VH-IVUS, an
algorithm constructed from post-mortem diseased human arteries, to correctly identify
swine pathology.
Regardless of the uncertainty and controversy regarding VH-IVUS, it has shown
clinical value in the PROSPECT trial. Presence of a VH-TCFA was an independent
predictor of MACE within the 3.4-year follow-up period (p<0.0001, HR=3.8), along with
the previously mentioned measures derived from grayscale IVUS [100]. These findings are
in accordance with two smaller prospective clinical trials [151, 152]. Yet, the majority of
the lesions identified as VH-TCFAs at baseline in the PROSPECT trial healed did not result
in MACE (Kaplan-Meier event rate = 4.4%) and those that did progress were severe lesions
associated with large plaque burden and/or small lumen [127]. This, again, raises the issue
of whether a TCFA identified by VH-IVUS definition is the same as the rupture-prone
histologically-defined TCFA. In 2016, the results of the first prospective randomized
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clinical trial using VH-IVUS were published, concluding rosuvastatin treatment decreased
VH-TCFA rate during 1-year follow-up [153]. However, the study suffered from
incomplete patient follow-up, underpowered sample size, biased patient population, and
lack of association with LDL-cholesterol levels. With each new VH-IVUS study, more
questions are raised rather than answered, leading some to question whether the tool is a
mere “gimmick” [154]. The role of VH-IVUS in identification of TCFA is limited until it
is further validated, independently of grayscale IVUS, with future studies.
1.4.4

Optical Coherence Tomography

The technique of optical coherence tomography (OCT) was co-developed in 1991 by
David Huang and colleagues [155]. After the first demonstration of successful in vitro
imaging of the peripapillary area of the retina and a coronary artery, many in the group
realized the endless potential of OCT as a high-resolution in vivo microscope. It has since
revolutionized the study of ocular diseases and routinely used by ophthalmologists to guide
clinical decisions [156]. The role of OCT in cardiology as an intravascular imaging
modality for evaluation of atherosclerosis is not as well-formed, but continues to progress.
OCT is analogous to IVUS, with the central difference being that signals are generated
via depth-resolved backscattered infrared light rather than reflected US (in the nearinfrared ranged, with a central wavelength from 1250 to 1350 nm). Due to the fast speed
of light, however, correlating a reflected light signal to position is nontrivial. OCT
overcomes this obstacle with use of a Michelson interferometer, a half-mirror apparatus
that splits monochromatic light into two beams directed to two “arms.” In catheter-based
OCT systems, one of the split light beams is diverted perpendicular to the catheter axis
towards the arterial wall, the “sample arm.” The other beam travels to a “reference arm”
with a mirror. Both the tissue and mirror will reflect the light. However, coherent
interference between the two returning light waves occurs only when light reflected from
the sample arm comes from a tissue depth equal to the length of the reference arm.
Incoherent reflections will wash out. Thus, interfering signal intensity at a certain reference
arm length can provide tissue tomography at a known depth. Furthermore, variable
translation of the reference arm mirror allows for incremental tissue penetration depth and
2D image reconstruction. Second-generation OCT systems, known as frequency domain
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OCT, vary the laser source wavelength with a stationary reference arm length. Penetration
depths can still be recovered via Fourier transform, and acquisition speeds are 15-50 times
faster than the traditional, time-domain OCT [83, 105, 157-162]. Rotation and pullback of
the OCT catheters are similar to mechanical IVUS systems.
OCT imaging via infrared light (1300-nm wavelength range) allows for high spatial
resolution, in the range of 2 to 20 μm [163-165]. Thus, OCT boasts a 10-fold greater
resolution than IVUS and is considered by some as the gold standard for measuring fibrous
cap thickness (Fig. 1.8) [54, 166]. Jang et al. measured fibrous caps using OCT in patients
presenting with acute MI versus those presenting with stable angina and found a significant
difference in median thickness (47.0 μm vs. 102.6 μm, p<0.05) [167]. Similarly Kubo et
al. showed that in vivo OCT measurement of fibrous cap thickness (49±21 μm) in 30
patients presenting with acute MI was more reliable than IVUS or angioscopy [166]. Others
have also validated the ability of OCT to measure change in cap thickness in patients with
acute MI between baseline and 9-month follow-up, with a significantly greater increase
seen in the group treated with statins compared to the control group [168, 169].
Furthermore, it has been shown that OCT can detect macrophage infiltration within fibrous
caps of plaques obtained at autopsy with 100% sensitivity and specificity in regions with
>10% CD68+ staining [37, 170, 171]. Lastly, a relatively new technique called
polarization-sensitive OCT can be used to measure collagen content and fiber thickness
within fibrous caps and plaques [172]. Thus, OCT has the ability to measure the
components of a fibrous cap that make it the most important determinant in plaque rupture:
sufficiently thin (<65 μm), inflammatory infiltrate, and loss of collagen content.
Beyond cap characteristics, OCT has shown the ability to identify plaque components,
similarly to VH-IVUS [164, 173-175]. One group performed ex vivo histological
correlation of 357 diseased coronary segments obtained at autopsy with OCT imaging. This
allowed characterization of lipid-rich plaques, fibrocalcific plaques, and fibrous plaques,
with sensitivities and specificities ranging from 87% to 95% and 94 to 100%, respectively
[176]. While OCT can resolve lipid-rich plaques as regions with low signal intensity, it
cannot easily distinguish between lipid pool and necrotic core [24, 177-179].
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Figure 1.8. OCT image of a TCFA and corresponding histology. A) OCT image of a TCFA, with arrow
indicating the thin fibrous cap. The rest of the plaque and composition, as shown by histology in (B), is not
visualized due to limited depth penetration and lack of compositional specificity. Adapted from Phipps et al.
(Circ Cardiovasc Interv, 2016).

A study performed on 79 diseased coronary segments showed misclassification of 41% of
lesions, primarily due to an inability to differentiate areas of heterogeneous composition
and low penetration depth [180]. Furthermore, a recent retrospective study of 1,474 patients
reported association between OCT-detected lipid-rich plaques with a 2-fold increase in
MACE at 2-year follow-up [181]. However, the methods defined lipid as a low signal
region with diffuse borders and failed to link lipid-rich plaque morphology to lesionspecific clinical events [181].
Recently, researchers are incrementally addressing this challenge with the development
of automated characterization algorithms to detect and quantify atherosclerosis via
attenuation coefficient [182-185]. As validated ex vivo against histopathology, vulnerable
plaque features were distinguished from other vessel wall components based on optical
properties: necrotic core and macrophage infiltration exhibit attenuation coefficients (µt) >
10 mm-1, while fibrous and calcific plaques have a lower attenuation coefficients [186-188].
These findings have been confirmed in vivo against near-infrared spectroscopy (NIRS) in
85 patients, in which a defined Index of Plaque Attenuation > 11 mm-1 differentiated
between TCFA and fibroatheroma (p<0.0001) [183].
A shallow penetration depth (2 mm) is the overarching limitation of OCT imaging. This
precludes it from imaging entire vessel walls, and therefore, assessment of total plaque
burden and remodeling. Given the complementary nature of OCT with IVUS, Zhongping
Chen and his group have successfully combined the modalities into a single catheter,
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validated in preclinical settings [189-192]. This high-speed combination catheter has the
advantage of two distinct contrast mechanisms: high-resolution of superficial structures
from OCT-based optical scattering and visualization of the entire vessel wall from IVUSbased acoustic scattering. Another significant and practical limitation is the scattering of
the 1300-nm wavelength light by red blood cells. To overcome this limitation, OCT
necessitates displacement of blood by saline or iso-osmolar contrast flush (typically 3.0
mL/s). Alternatively, for OCT pullbacks of longer arterial segments, the artery may be
occluded by a balloon proximally. However, this increases the risk of myocardial ischemia
as seen by electrocardiograph changes and chest discomfort in the patient [54, 83, 157-159,
193, 194]. This risk has been minimized by the fast pullback speed of commercial devices
(20 mm/s and 100 fps) and, in a five-year retrospective analysis, OCT-related complication
rate did not differ from IVUS procedures (p=0.6) [195].
Despite its limited penetration depth and additional procedural requirements, OCT has
the pivotal and distinct capability of measuring TCFA cap thickness with unmatched
resolution. Furthermore, novel automated algorithms using attenuation coefficient may
reveal additional value in characterization of plaque phenotype. Validation will require
large natural history studies and more robust data, but it will not be surprising if OCT
proves to be a synergistic component of future multimodal imaging platforms.
1.4.5

Near-infrared Spectroscopy

Diffuse reflectance near-infrared spectroscopy performs nondestructive identification
of chemical components in biological tissue. NIRS works on the principle that, when a
broadband light source (containing light over a range of wavelengths) encounters tissue,
molecules become excited and enter a vibrational state in which they absorb light in the
NIR range (750-2500 nm). This absorbance (y-axis) is measured and reported as a function
of wavelength (x-axis) to form a spectrum characteristic of the imaged tissue. Chemical
composition of the tissue is recovered via spectral analysis. Imaging in the NIR window is
particularly valuable because both hemoglobin and water have relatively low absorbance
at these wavelengths, making it compatible with blood [105, 196-198]. Current commercial
catheters are capable of approximately 8000 real-time chemical assessments per 100 mm
at a pullback speed of 0.5 mm/s [108, 199].
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NIRS imaging for chemical composition was first demonstrated in atherosclerotic
plaques from hypercholesteremic rabbits in 1993 [200]. This was further validated in 1996
in human carotid plaques obtained via endarterectomy that were compared against gel
electrophoresis compositional analysis [201]. In 2002, Moreno et al. were the first to
exploit the spectral signatures of plaque components obtained by NIRS to characterize a
vulnerable plaque [202]. They analyzed 199 human aortic samples obtained at autopsy with
NIRS and histology to identify lipid pool, thin fibrous cap, and inflammatory infiltrate.
Half the samples were used as a reference set to construct a predictive algorithm, while the
remaining samples were used to conduct blinded predictions. NIRS demonstrated excellent
lipid detection, with a sensitivity and specificity of 90% and 93%, respectively. Substantial
progress was made in two parallel studies that presented feasibility of a catheter-based
NIRS system. The ex vivo study developed a predictive algorithm to detect lipid core
plaques (LCP) through blood using coronary segments from 33 human autopsy hearts. Next,
they showed prospective, double-blinded accuracy in detection of LCPs in 51 validation
autopsy hearts (AUC=0.80 in ROC analysis) [203]. The parallel SPECTroscopic
Assessment of Coronary Lipid (SPECTACL) trial subsequently demonstrated in vivo
spectral similarity in 83% of enrolled patients [204]. Today, interpretation of NIRS data is
completed by a proprietary computer-based algorithm based on these previous validation
studies [203-205]. The automated analysis transforms NIR spectra into a colorized
representation of the probability of LCP presence from 0 (red) to 1 (yellow). This is
displayed visually as a fold-out map of the total vessel termed a “chemogram,” in which
each colored pixel represents 0.1 mm length (x-axis), 1o angle (y-axis), and the LCP
probability. This is also generated per frame, displayed circumferentially around a
grayscale IVUS image, with which it is paired commercially (Fig. 1.9). The calculation of
a lipid core burden index (LCBI) score provides a quasi-quantitative measure of LCP
presence. LCBI is calculated as the fraction of valid pixels in which LCP probability is
greater than 0.6, multiplied by 1000. The maximum LCBI can also be calculated for narrow
(4 mm) regions of interest (maxLCBI4mm) [59, 108, 110, 206, 207]. In the past five years,
many studies using NIRS-IVUS have revealed strong association between elevated
maxLCBI4mm (and LCBI) and cardiovascular outcomes in CAD patients [199, 208-217].
Furthermore, other studies have shown a significantly greater reduction in maxLCBI4mm in
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patients randomized to a high-dose statin therapy group compared to the standard dose
group [218-220]. Yet, despite the plethora of completed research using NIRS-IVUS, there
is no consensus of a maxLCBI4mm threshold for prediction of MACE. In 2016, Madder et
al. reported a threshold maxLCBI4mm >400 as predictive for differentiation of ST-segmentelevation myocardial infarction culprit from nonculprit segments and predictive of future
MACE at 1-year follow-up (p<0.001) [213, 216]. In 2017, a single-center prospective,
observational study reported association between quartiles and continuous maxLCBI4mm
values and higher risk of MACE at 4-year follow-up. They found a maxLCBI4mm >360
(inter-quartile range 4) to be predictive of future MACE (p<0.001, HR=3.58) [221]. It is
anticipated that more precise maxLCBI4mm cut-offs will be determined within this year
after the completion of two large prospective outcome trials: the Lipid-Rich Plaque (LRP)
study with a 1,562 patient cohort and the PROSPECT II ABSORB study with a 900 patient
cohort [222].
The overarching limitation of NIRS is an inability to provide explicit depth information
regarding lipid deposition. Spectral data is collected within a depth of 1 mm or less and no
resolution for axial distance from the catheter tip probe. This lack of depth-resolution stunts
the capability of NIRS for localization of the lipid core in relation to other plaque
components (i.e. fibrous growth, calcification, lumen border), quantification of the lipid
core (i.e. volume and cross-sectional area), and differentiation between superficial and
deep lipid depots (i.e. plaque lipid versus perivascular lipid) [58, 59, 199]. Thus, there is a
reliance upon semi-quantitative metrics such as LCBI and maxLCBI4mm, for which the
interpretation and prognostic value are not yet clear.
Furthermore, fibrous cap thickness and macrophage inflammation are currently not able
to be detected, but may be possible with the advent of extended bandwidth US transducers
and sensing of inflammatory markers such as change in temperature and pH [223, 224].
Ultimately, the aforementioned prospective observational studies will determine the
clinical prognostic value of NIRS for detection of vulnerable plaques and subsequent
cardiovascular events. The outlook is promising, as it is currently the only FDA approved
hybrid-modality catheter and has been used safely in over 80 hospitals worldwide and
16,000 patients since 2010 [222].
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Figure 1.9. NIRS chemogram and NIRS-IVUS images. A) Chemogram showing a 2D representation of
lipid (yellow) and non-lipid containing tissue (red) with x-axis as the longitudinal pullback direction and axis as the longitudinal pullback direction and y-axis the rotation degree. B) Grayscale IVUS image shown
in the inset, with NIRS information shown circumferentially suggesting no lipid is present at this crosssection of the artery. C) Grayscale IVUS, with NIRS information suggesting lipid is present with high
probability from approximately 7 to 11 o’clock. However, the precise location and depth within the plaque
is not given due to lack of depth resolution.

1.4.6

Photoacoustic Imaging

Intravascular photoacoustic (IVPA) imaging has been the latest modality added to the
list of promising catheter-based tools in the detection for vulnerable plaque. Photoacoustic
(PA) imaging has the advantage of both optical- and acoustic-based modalities: chemical
selectivity without the use of labeling dyes and ample penetration depth. In PA imaging,
the targeted tissue is exposed to a non-destructive nanosecond laser pulse. Absorption of
optical energy results in molecular excitation and release of heat, which subsequently
causes small thermal expansion. This expansion imparts a transient pressure rise that
propagates acoustic waves, detected by an US transducer with depth location resolved via
propagation time delay [225-229]. In IVPA catheters, the optical fiber and US transducer
have been miniaturized to fit and interrogate the same field of view. PA images are coregistered with traditional US imaging, inherently performing as a dual-modality device
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[230-235].
PA imaging has the ability to resolve different plaque components based on excitation
wavelength, with lipids being the most successfully studied and validated due to their
abundance in C-H bonds and large absorption coefficient [229]. 1.7 μm and 1.2 μm have
been discovered to be suitable laser wavelengths representing C-H bond first and second
overtone transitions, respectively, at which lipid-specific spectral features are generated
with minimal water absorption (Fig. 1.10A). Thus, several groups have since exploited
these optical windows to image lipid cores of atherosclerotic plaques [226, 230, 232, 233,
236-250]. Using 1.7 µm wavelength and a combined IVPA-US catheter system, Bo Wang
et al. successfully imaged the lipid core of an atherosclerotic rabbit aorta in vivo and an
atherosclerotic human coronary artery ex vivo, both of which correlated with
histopathology in a limited proof-of-concept study (Fig. 1.10B, C) [244-246]. Following,
Zhang et al. reported a larger systematic, longitudinal in vivo and ex vivo validation study
performed in atherosclerotic rabbits that showed quantitative correlation between lipid-rich
plaque images collected by IVPA and histopathology [251]. Despite the many translational
shortcomings of both works, it paved the way for future incremental advances [252].
Challenges such as image acquisition speed due to low laser pulse frequency had been an
overarching limitation, but addressed over the past 2 years with advancements in new highspeed excitation sources, with two groups demonstrating real-time imaging speeds >20 fps
[253, 254]. Furthermore, co-registration between PA and US channels has been improved
by orientation of probe components in various successful designs (Fig. 1.10D-F) [233, 250,
255]. Lastly, this past year, Wu et al. performed the first in vivo demonstration of real-time
IVPA-US imaging in a swine coronary artery through luminal blood [253, 256].
Furthermore, this study incorporated a protective polyethylene sheath enclosing the
catheter (outer diameter: 1.3 mm), demonstrating safety of the imaging protocol and
catheter flexibility in reaching the coronary artery via carotid access.
These breakthroughs have propelled IVPA imaging from being an experimental
technique to one clinically translatable in the foreseeable future. Yet, there remain
significant limitations with IVPA imaging [257]. While IVPA imaging has been shown to
be acceptable through blood, sensitivity is still optimal and preferred with blood clearance
or dilution with expensive saline heavy water (D2O) [253, 254].
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Figure 1.10. IVPA imaging theory, example, and catheter probe designs. A) Optical spectra showing
absorption coefficient of lipid (green line) exceeds that of water (black line) at optical windows around 1.2
µm and 1.7 μm, thus making these wavelengths optimal for IVPA imaging. B, C) In vivo imaging of the
abdominal aorta of an atherosclerotic rabbit reveals plaque lipid in the PA channel shown in B and localized
within the artery wall when merged with the US channel shown in C. D) Front-to-back catheter design
introduced by the Emelianov group and advanced by many others, in which there is an offset between the
optical path reflection and transducer side-firing. This design has been miniaturized by the van Soest group
to 1.3 mm in diameter with a sheath. E) Coaxial catheter design introduced by the Cheng group in which a
ring-shaped transducer around the optical fiber allows for uniform optical and acoustic path overlap. However,
further miniaturization of ring-shaped transducers is not currently feasible, limiting the probe diameter to a
clinically-incompatible diameter of 2.9 mm. F) Collinear catheter design introduced by the Cheng group in
which a series of reflections also allows for uniform optical and acoustic paths overlap in a smaller diameter
probe (1.6 mm with sheath, data not yet published). This design has also been modified to reduce the number
of ultrasound reflection surfaces and minimize signal loss by positioning of the transducer at a 10o angle for
direct interrogation of tissue (quasi-collinear design, data not yet published). Panels A, B and C, D, E, and F
adapted from Hui et al. (Photoacoustics, 2016), Wang et al. (Ultrasound Med Biol, 2012), Karpiouk et al.
(Rev Sci Instrum, 2010), Wang et al. (Sci Rep, 2014), and Cao et al., (Sci Rep, 2016), respectively.

In addition, PA signals are generally weaker and contain lower frequency spectral
components (<20 MHz), thus must be paired with extended-bandwidth transducers to
obtain the best PA and US images [258]. Also, most common soft polymer sheath
components contain the same C-H bonds that provide lipid contrast, creating a challenge
in finding a material sufficiently transparent to not compromise optical and acoustic image
quality [61]. The complete catheter diameter must also be further miniaturized to 1 mm or
less, comparable to current commercial probes. While overcoming the aforementioned
hurdles are within reach, the most pressing limitation remains a lack of validation of IVPA-
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US imaging and classification algorithms in fresh human coronary arteries against goldstandard histopathology. In all previously overviewed modalities, FDA-approval,
commercialization, and clinical trials were only possible after a publication of a key ex vivo
validation study [135, 164, 203]. This, however, takes considerable effort and time: 1)
practically for the collection of a sufficient n of fresh human coronary specimens that
encompass a wide range of plaque phenotypes, 2) reproducibility of catheter fabrication,
operation, and performance, and 3) calibration of image processing algorithms to match
PA signal with lipid with adequate specificity and sensitivity. For IVPA researchers to meet
these critical milestones within the next 5 years is foreseeable and in progress.
Furthermore, there is optimism for IVPA imaging for the identification of additional
vulnerable plaque components. Spectral analysis of PA signals can be used to identify
cholesterol esters versus pro-inflammatory cholesterol crystals [259-262]. Inflammation
can also be visualized via exogenous absorbers targeted for macrophages or matrix
metalloproteinases [263-265]. In addition, fibrous cap collagen content can be identified
via multispectral imaging [247, 266, 267]. Lastly, depth resolution of PA imaging can
differentiate between deep and superficial lipid depots, identifying perivascular adipose
tissue (PVAT) which is a known mediator of atherogenesis and providing precise spatial
location of lipid-rich plaque cores [242, 255, 267-269].
1.4.7

Summary

While each of the presented modalities offer an independent advantage in TCFA
identification, they also leave something to be desired (Table 1.1). Angiography has been
and will remain the gold-standard for visualizing the coronary arterial tree, but its inability
to image the vessel wall precludes it from vulnerable plaque detection [270]. Grayscale
IVUS has provided interventional cardiologists with the means to assess lumen dimensions,
plaque morphology and burden, and positive remodeling [74, 85, 132]. Yet, its lack of
resolution to define the thin fibrous cap of TCFAs with inflammatory infiltrate and
characterize the lipid-rich necrotic core has opened doors for alternative tools. Despite the
excitement surrounding VH-IVUS, which aims to characterize plaques via RF analysis of
the same signal of grayscale IVUS, its ability to define plaque composition has limited
validity [32, 127]. OCT undoubtedly presents the best resolution and ability to define
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fibrous cap thickness, but lacks sufficient penetration depth to visualize the entire vessel
wall for plaque characterization [158, 159, 271]. To date, NIRS has proven to be the most
valuable in detection of lipid-rich plaques, but does not have inherent depth resolution
needed to locate the core relative to lumen [196, 197]. IVPA can potentially provide
detection of many plaque components with the advantage of depth resolution, but is
currently limited to lipid detection and has not been thoroughly validated [226, 257].
Thus, the defining features of TCFAs—lipid content, cap thickness, inflammation, and
positive remodeling—can all be visualized by various intravascular imaging modalities.
However, this is not accomplished by a single tool alone. The development of dual- or even
triple-modality catheters that provide complementary structural and compositional
information is already underway, with NIRS-IVUS commercially available and IVPAIVUS, OCT-IVUS, OCT-NIRS all in the preclinical phase [57-61, 109, 272-274].
The combined advantages of hybrid modalities will provide experts with detailed and
more accurate characterization of vulnerable plaque pathophysiology. Evidence from the
few prospective, observational clinical trials have suggested lesions that appear vulnerable
for rupture on imaging are limited in number and not necessarily the ones that progress to
a thrombogenic event. This discrepancy highlights the need for in vivo tools to study plaque
rupture and vulnerable plaque prevalence, as our current understanding is limited to
findings from post-mortem histopathology. This follows the truism that while “pathologists
are always right, they arrive too late” [58, 61, 275, 276].
Beyond proving their value as research tools, it is the ultimate desire for intravascular
imaging to be adopted for clinical decision making. For instance, early identification of
patients with high-risk lesions could permit prophylactic intervention via bioresorbable
vascular scaffolds or recommendation for aggressive pharmaceutical therapy, such as
PCSK9 inhibitors or high-dose statins [277-283]. Whether intravascular imaging tools can
advance to provide the prognostic information necessary to curb CAD-associated
morbidity and mortality is still uncertain [32, 60, 154, 275, 280, 284-288]. This uncertainty
should intensify our efforts towards the validation, optimization, and hybridization of
intravascular imaging tools for vulnerable plaque detection.

Table 1.1 Summary of Intravascular Imaging Modalities

Optical
scattering

NIRS
(-IVUS)
Optical
absorption

IVPA
(-US)
Optical
absorption

150-250 µm
> 5 mm

2-20 µm
< 2 mm

N/A
1-2 mm

80-200 µm
5-6 mm

+++

+++

-

+++

+++

+
CU

++
CA/CS

+++
++
+
CA/CS

+
+++
CA/CS

*
+++
*
PCS

Technology

Angiography

IVUS

VH-IVUS

OCT

Contrast mechanism

Radiopaque dye

Acoustic
scattering

Acoustic
spectrum

Axial Resolution
Penetration Depth

130-200 µm
N/A

100-120 µm
> 5 mm

Positive remodeling

-

Fibrous cap
Lipid core
Inflammation
Current Status

CU

Capability of each modality for the assessment of thin-capped fibroatheroma hallmarks is presented with the following scale: +++, excellent; ++, good; +,
possible; -, not currently possible; *, under investigation; The capability of NIRS and IVPA to assess positive remodeling and fibrous cap were evaluated with
the assessment that they are paired with IVUS, as they are only commercially available or being developed in that form.
CU, clinically used; CA, clinically available; CS, clinical studies ongoing; PCS, preclinical studies
Modified with current evidence from following references: [24, 36, 55, 56, 61, 105, 113, 128, 157, 159, 162, 175, 194, 206, 226, 289-292]
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Scope and Aims of the Current Investigation
We hypothesize a dual-modality IVPA-US imaging catheter can detect, localize, and
quantify lipid content in atherosclerotic arteries, providing prognostic value for the early
identification and characterization of high-risk plaques vulnerable for rupture. For this
work, we focus on preclinical validation of our IVPA-US imaging system. Our approach
towards validation includes systematic comparison of IVPA-US imaging to gold-standard
histopathology, and previously validated imaging modalities such as angiography,
grayscale IVUS, and NIRS-IVUS. Our investigation ranges from ex vivo interrogation of
atherosclerotic human coronary arteries to in vivo assessment of atherosclerotic peripheral
arteries in swine models of vascular disease. The results of our steps towards validation in
a heterogeneous sample set is presented in the following chapters, in which we show
agreement between IVPA-US imaging, histopathology, imaging results from existing
modalities, and metabolic phenotype. We further demonstrate the competing advantages
of IVPA-US imaging over existing intravascular tools for localization and quantification
lipid content, such as sensitivity for early atherosclerotic changes, differentiation between
superficial and deep lipid, and localization of lipid cores in relation to other plaque features.
The highly interdisciplinary nature of this work required collaboration with experts in
spectroscopy, optical engineering, microfabrication, materials engineering, signal
processing, cardiovascular pathophysiology, and clinical cardiology. The collective work
of many individuals has resulted in significant advancement towards our central hypothesis
not only through comparative validation, but also, along the way, critical milestones
necessary for future clinical translation. These achievements include miniaturization of the
probe within a protective sheath, automated high-speed imaging with real-time display,
sensitivity across a large depth through luminal blood, refined post-processing algorithms,
and analysis of photoacoustic spectral characteristics. In this thesis, the aforementioned
technical achievements are discussed only within the context of validation in biological
samples.
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2. ASSESSMENT OF EARLY ATHEROSCLEROSIS IN CAROTID
ARTERIES OF DYSLIPIDEMIC OSSABAW SWINE BY IVPAUS: AN EX VIVO VALIDATION STUDY
Rationale
The present study aims to demonstrate the capability of an intravascular photoacousticultrasound (IVPA-US) imaging catheter for depth-resolved assessment of lipid deposition
in fixed and fresh carotid artery specimens from Ossabaw swine with dyslipidemia and
metabolic syndrome. To that end, we compare IVPA-US imaging results to gold-standard
histopathology and near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), a
previously validated and clinically-approved hybrid modality for lipid detection. We
provide this comparison to establish agreement between competing modalities and also
highlight the relative advantages of each. Imaging was conducted in carotid artery
specimens from swine due to its large lumen diameter and muscular nature, providing
unambiguous structural features on IVUS. Furthermore, we use the Ossabaw miniature
swine model, as it has been previously well-characterized to develop dyslipidemia and the
features of metabolic syndrome when induced with a pro-atherogenic diet [293-296]. The
presence of subclinical vascular disease in Ossabaw swine provides an opportunity to
investigate the sensitivity of both modalities for the detection of early-stage (or pre-clinical)
atherosclerosis [280]. Portions of the work presented in this chapter have been published
previously in Scientific Reports and have been intentionally reproduced here with
permission [255].
Materials and Methods
2.2.1

IVPA-US Imaging System and Data Acquisition

A custom-built potassium titanyl phosphate (KTP)-based optical parametric oscillator
(OPO) emitting at 1.7 µm with a repetition rate of 500 Hz and pulse width of 13 ns was
used as the optical excitation source for photoacoustic imaging work presented in this
chapter [297]. We used 1.7 µm due to the absorption peak of lipids and valley of water at
this wavelength (Fig. 1.10A) [228, 266]. Although there is not a distinct difference in
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absorption coefficients of lipid and water at 1.7 µm, the generated PA signal from lipid is
substantially greater due to the larger Gruneisen parameter [229]. Light was coupled to the
catheter via a multimode fiber (MMF) and an optical rotary joint. The pulse energy at the
catheter probe tip was controlled to 120 µJ or less, corresponding to an energy density of
approximately 30 mJ/cm2 at the tissue surface, below the 1.0 J/cm2 ANSI safety standard
for skin at 1.7 µm [298]. Cross-sectional scanning and longitudinal pullback was enabled
by a rotational motor, linear stage, and torque coil. Sequential IVPA and IVUS signals
were generated and detected with a 10 µs time delay (37000-424 Datapulse Pulse
Generator, Datapulse, Inc.) and a single-element transducer (0.5 x 0.6 x 0.2 mm3, 42 MHz,
60% bandwidth; Blatek, Inc., Point-Claire, QC, Canada). Signals were amplified by a
factor of 39 dB and acquired digitally via a data acquisition card (ATS9462 PCI express
digitizer, AlazerTech, Canada) with 16-bit digitization and 180 MS/s rate to LabView
software, with quasi-real-time display. The number of A-lines collected per image was 500,
at a 1 frame per second (fps) imaging speed (catheter rotation of 1 revolution per second).
A collinear catheter design was used, as shown in Figure 2.1. Briefly, the distal end of
the MMF fiber (FG365LEC, Thorlabs, Inc., Newton, NJ) was polished to 45o for
ultrasound wave reflection from a single-element transducer placed parallel to the fiber and
facing the polished surface. Optical light delivery still propagates in a forward direction
from the polished end, thus optical and ultrasound paths are collinear after encountering
the polished surface. Next, a 45o rod mirror (1 mm diameter; Edmund Optics, Inc.,
Barrington, NJ) reflects both paths perpendicular to the catheter axis for interrogation of
the vessel wall. The total diameter of the catheter tip probe was 1.6 mm and did not include
an outer protective sheath.
The IVPA-US collinear catheter system demonstrated a PA axial resolution of 81 µm
and lateral resolution of 372 μm at a radial distance (i.e. depth) of 2.2 mm, as measured by
a 7 μm-diameter carbon fiber in deuterium oxide (D2O) as a standard. At greater imaging
depths up to 6.2 mm, PA axial resolutions remained around 80 µm, while lateral resolutions
ranged from 350 µm to 430 µm. Notably, optical and ultrasound paths in this collinear
design were found to overlap at a depth of 6.2 mm. Further characterization of imaging
system performance, description of the system architecture, and full fabrication method of
the collinear catheter are found in detail in work previously published by our group [255].
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Figure 2.1. Collinear IVPA catheter probe. A) Exploded-view schematic of the collinear catheter. B)
Assembled view of the collinear catheter. C) Zoom-in view of the catheter probe tip, illustrating collinear
overlap between optical and acoustic paths after reflection of the polished multimode fiber (MMF) surface.
D) Photograph of the fabricated catheter probe tip and detailed structure (inset). Reproduced from Cao et al.,
(Sci Rep, 2016).

2.2.2

Animal Care and Use

This protocol was performed according to the Guide for the Care and Use of Laboratory
Animals and approved by the Indiana University School of Medicine Animal Care and Use
Committee [299]. Ossabaw miniature swine (n=16) were fed a hypercaloric, atherogenic
diet for 6 months (43% of total caloric intake from fat, 16% from protein, and 41% from
carbohydrates, 1000 g/day). Swine were individually housed with free access to water.
Development of metabolic syndrome (MetS) and pre-clinical coronary artery disease
(CAD) in this naturally progressive animal model of human disease has been characterized
in previous work [294, 296]. Metabolic data including body weight, total cholesterol,
triglycerides, fasting glucose, and blood pressure were collected to confirm induction of
MetS and dyslipidemia in the animals. A carotid artery specimen that we investigated after
formalin-fixation was harvested from a swine in a different study, in which diet
composition and duration varied slightly (fed for 12 months, 600 g/day with the addition
of 19% kcal from fructose, supplemented with cholesterol (2%), hydrogenated coconut oil
(5%), hydrogenated soybean oil (8%), cholate (1%) and high-fructose corn syrup (5%) by
weight; KT-324, Purina Test Diet, Richmond, IN).
Anesthesia was induced via intramuscular injection of 5.5 mg/kg telazol (Webster
Veterinary, Devens, MA) and 2.2 mg/kg xylazine (Fort Dodge Animal Health, Fort Dodge,
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IA). Next, pigs were intubated and maintained with 2-4% isoflurane mixed with 100%
oxygen. The isoflurane level was adjusted during the in vivo procedure to maintain stable
hemodynamics. A 7 Fr introducer sheath was inserted in the right femoral artery of the
swine and heparin was administered (200 U/kg). Next, a 7 Fr guiding catheter (Cordis,
Bridgewater, NJ) was advanced to access the carotid artery bifurcation. An angiogram with
Omnipaque contrast (iohexol) was recorded to visualize carotid vascular anatomy. Next, a
3.2 Fr, 45 MHz commercial IVUS catheter (Revolution, Volcano, Corp., Rancho Cordova,
CA) was advanced 90 mm distally over a percutaneous transluminal coronary angioplasty
guidewire (Boston Scientific, Natick, MA) into the right carotid artery. Automated IVUS
pullback was performed and recorded at 0.5 mm/s. In vivo IVUS imaging was not
performed for the carotid artery specimen that we investigated after formalin-fixation.
Following imaging, the animal was euthanatized by isoflurane overdose and cardiectomy.
Following euthanasia, the carotid artery bifurcation was isolated and dissected out of
the animal for further removal of surrounding adventitia. The bifurcation branch point was
cannulated with a shortened 8 Fr hemostatic introducer sheath and sutured securely. Next,
the distal ends of the left and right carotid artery and the right subclavian artery side branch
were ligated with suture (3-0 black braided silk, Ethicon, Inc., Somerville, NJ) to allow for
pressure-perfusion. Arteries were maintained in Eagle’s Minimal Essential Medium with
HEPES (EH) storage solution at 4 oC and imaged within 96 hours after death. A separate
carotid artery specimen was formalin-fixed in 10% phosphate-buffered formalin for 24 to
48 hours, then grossly sectioned into 3 to 4 mm segments. A segment of interest, with
suspected plaque on stereo microscope imaging, was placed in 2.5% agarose gel
surrounding the artery and submerged in D2O for imaging.
2.2.3

Ex Vivo Imaging and Histology

For carotid arteries imaged fresh, the vessel was pinned in a Sylgard® 184 Silicone
Elastomer (Dow Corning, Corp., Midland, MI) tray and submerged in 1X phosphatebuffered saline (PBS), pH 7.4 (Life Technologies, Carlsbad, CA) at room temperature and
was perfused to mimic physiologic pressure during imaging. Perfusion was performed
manually with a large-barrel syringe at an approximate rate of 100 to 140 mL/min, which
translates to an approximate pressure of 80 to 120 mmHg, as measured experimentally
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using a coronary pressure wire (ComboWire XT, Volcano, Corp.). A 3.2 Fr, 45 MHz IVUS
catheter (Revolution, Volcano, Corp.) was introduced into the carotid artery via hemostatic
introducer sheath and advanced to a maximal distal point, where the artery was ligated (Fig.
2.2). The vessel was perfused as described during an automated pullback at 1.0 mm/s and
imaging speed of 30 fps. Pullback was complete when the imaging catheter retreated into
the introducer sheath. This procedure was repeated with a 3.2 Fr, 40 MHz NIRS-IVUS
catheter (TVC Insight, Infraredx, Inc., Burlington, MA) at a 0.5 mm/s pullback speed and
16 fps imaging speed. Lastly, the procedure was repeated using our 4.8 Fr, 42 MHz IVPAUS collinear catheter at a pullback speed of 0.2 mm/s and 1 fps imaging speed. Pressureperfusion was not performed for IVPA-US ex vivo imaging procedures, due to the lack of
a surrounding protective sheath and the need for a modified guiding catheter to permit
resistance-free pullback through the introducer sheath. Alignment of pullbacks from
different modalities was conducted via identification of common anatomical landmarks,
such as the right subclavian artery branch and the carotid bifurcation. The fixed carotid
artery specimen embedded in agarose gel was imaged by our IVPA-US imaging system in
a static D2O environment at several cross-sectional locations within the segment, rather
than a continuous pullback. Ex vivo grayscale IVUS and NIRS-IVUS imaging were not
performed in this specimen.

Figure 2.2. Ex vivo imaging setup for fresh carotid artery imaging. Carotid arteries are cannulated with a
modified hemostatic introducer sheath. Distal ends and side branches are ligated (shown here with a
hemostatic clip) to allow for physiologic pressure perfusion during imaging.

To maintain vessel morphology, fresh carotid arteries were pressure-fixed using 10%
phosphate-buffered formalin with a large-barrel syringe at approximately 25 mL/min for
30 min and placed in formalin for 24 to 48 hours. The arteries were grossly sectioned in 3
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to 5 mm segments. Next, each segment was paraffin embedded, thin sectioned, and stained
for hematoxylin and eosin (H&E) and Russel-Movat’s pentachrome. For segments
identified as positive of region interests on NIRS-IVUS imaging and IVPA-US imaging,
multiple thin sections were cut serially at 250 µm intervals. The carotid artery specimen
that was imaged after formalin-fixation was cryoprotected in a 25% sucrose/PBS wash for
48 hours, after which the tissue was cryosectioned and stained with oil red O and H&E
counterstain. Area calculations on intravascular and histology images were performed
using ImageJ software (1.48v, National Institutes of Health, USA).
Results
2.3.1

IVPA-US Imaging of a Fixed Carotid Artery from an Ossabaw Swine

Ossabaw swine from which the right carotid artery was harvested for imaging had a
91.4% increase in total body weight from the start of hypercaloric atherogenic diet to
sacrifice (52.5 kg to 100.5 kg). The swine, however, did not have elevated plasma lipids
(total cholesterol: 63 mg/dL, triglycerides: 89 mg/dL). Despite a lipid panel within normal
limits, we observed suspected stenotic plaque under a stereoscopic microscope in a
segment of the carotid artery. After formalin-fixation and being embedded in agarose gel,
we performed IVPA-US imaging of the segment of interest. IVUS, IVPA, and merged
cross-sectional images are shown in Figure 2.3A-C. On IVUS imaging (Fig. 2.3A), we
observed the characteristic three-layer appearance of the muscular carotid artery. We used
the intimal border to identify the original lumen, which then revealed an area of strong
echogenicity suggesting the presence of an eccentric fibrous plaque. On IVPA and merged
imaging (Fig. 2.3B-C), we found the suspected plaque area had strong PA signal,
suggesting the presence of a lipid-rich core. On gross imaging of the embedded artery (Fig.
2.3D) and ORO histology (Fig. 2.3E), we confirm the presence of an eccentric fibrofatty
plaque. There is some ambiguity on the ORO histological section, as we do not see the
characteristic red color specific for lipid. Instead, there is a tear where we would suspect
lipid to be. This is a histological artifact of cryosectioning heterogeneous arteries with soft
plaque components that make for a poor cutting substrate on the cryotome.

Figure 2.3. Ex vivo IVPA-US imaging of a swine carotid artery. A) IVUS cross-sectional image, with internal elastic lamina and external elastic lamina borders
of the characteristic three-layer appearance traced (green). A suspected eccentric plaque encroaching the lumen is highlighted (blue). B) IVPA image showing lipid
(red). C) Merged IVPA-US image shows a strong area of PA signal within the suspected plaque region, suggesting a lipid-rich core. D) Gross photograph of artery
segment with the stenotic plaque traced (inset). E) ORO histology showing possible presence of lipid (insets, arrowhead). Horizontal and vertical axis tracings in
A-C are 1 mm apart. Reproduced from Cao et al., (Sci Rep, 2016).
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2.3.2

Comparative IVPA-US and NIRS-IVUS Imaging of Fresh Carotid Arteries
from Ossabaw Swine with Metabolic Syndrome

Ossabaw swine from which we imaged fresh carotid arteries by angiography, in vivo and
ex vivo grayscale IVUS, ex vivo NIRS-IVUS, and ex vivo IVPA-US exhibited the features
of MetS, including glucose intolerance, obesity, and dyslipidemia (total cholesterol: 907 ±
180 mg/dL, triglycerides: 261 ± 137 mg/dL). For alignment across all intravascular
imaging modalities, we relied upon the anatomical landmarks of the carotid bifurcation and
the subclavian artery branch. In the 15 of 16 carotid arteries, we were unable to perform
comparative analysis due to either inadequate anatomical alignment of pullbacks or no
positive region of interest with suspected lipid. In the remaining sample, we successfully
identified anatomical landmarks on all modalities and also established a positive region of
interest (Fig. 2.4) with suspected lipid deposition based on NIRS-IVUS findings. In this
carotid artery sample, the swine had a total cholesterol of 600 mg/dL, triglycerides of 16
mg/dL, and weight of 70.8 kg at sacrifice (153% increase during atherogenic diet period).
Angiography with contrast of the carotid artery bifurcation showed a non-obstructed
lumen (Fig. 2.5A). Grayscale IVUS imaging of the right carotid artery did not reveal any
vascular disease, both in vivo (Fig. 2.5B) and ex vivo (Fig. 2.6A). Ex vivo NIRS-IVUS
imaging of the right carotid artery showed high probability of lipid at the carotid bifurcation
point (Fig. 2.6B), with a maxLCBI4mm of 620 distal to the bifurcation and 469 proximal to
the bifurcation (Fig. 2.7). On ex vivo IVPA-US imaging, we also detected lipid signal
proximal to the carotid bifurcation point, as possible raised lesion with an estimated area
of 0.62 mm2 (Fig. 2.6C, D). Furthermore, we repeated imaging within this segment (0.9
mm) at a slower pullback speed of 0.09 mm/s for high-resolution 3D reconstruction which
confirmed our findings and showed the lesion as a continuous streak (Fig 2.8). On
histopathology of this positive region of interest (proximal to the carotid bifurcation and
distal to the right subclavian artery branch), we observed a raised lesion with an area of
0.70 mm2. Based on the paucity of extracellular structure and anucleate space of the lesion,
we characterized the lesion as early pathologic intimal thickening (Fig. 2.6E, F) [300] . A
distal portion of the artery as shown in Figure 2.4 served as a negative control, as no disease
or lipid deposition was observed all modalities. Histology confirmed healthy artery
morphology. (Fig. 2.9).
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Figure 2.4. Gross image of a fresh carotid artery. Gross image of the fresh carotid artery sample in which
we identified, by multiple modalities, a positive region of interest (highlighted green) immediately proximal
to the carotid bifurcation and a negative region of interest (highlighted red) in the distal portion of the artery.

Figure 2.5. In vivo angiogram and grayscale IVUS imaging. A) Angiogram of the carotid artery
bifurcation, showing no stenotic lesions. B) Grayscale IVUS cross-sectional frame, showing a three-layer
appearance and no disease. The relative position of this frame in the carotid artery is indicated in (A) by an
arrowhead.

Figure 2.6. Ex vivo imaging frames and histopathology of identical cross-sections at the positive region of interest, proximal to the carotid bifurcation. We
identified identical position on all imaging and histological sections based on the bifurcate anatomy. A) On grayscale IVUS, we did not observe any disease. B)
On NIRS-IVUS, we observed a high probability of lipid (yellow) at approximately 2 to 4 o’clock. C) Merged IVPA-US image shows lipid (red) on the intimal
surface. D) We calculated the area with strong lipid signal on IVPA as 0.62 mm2. E, F) Movat’s pentachrome stained section, showing a raise lesion (traced) with
a lesion area of 0.70 mm2.
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Figure 2.7. NIRS chemogram at the positive region of interest, proximal to the carotid bifurcation. A)
The 2D chemogram shows the positive region interest as having a high probability of lipid. The maxLCBI4mm
were calculated for two regions (outlined in gold), distal to the bifurcation (620) and proximal to the
bifurcation (469). Also shown is the block chemogram above the x-axis scale, which summarizes the total
chemogram into 2-mm colorized blocks representing the probability of lipid into four distinct colors from
red (low) through orange and tan to yellow (high). B) NIRS block chemogram in relation to the longitudinal
grayscale IVUS image. The regions within which the maxLCBI4mm were calculated are outlined in gold and
the left carotid artery is indicated by an arrowhead.

Figure 2.8. 3D reconstruction of the positive region of interest. Lipid deposition, as a continuous streak, is visible (red) in this merged 3D reconstruction of a
0.9 mm segment. (A-F) Panels advance in a clockwise rotation, showing lipid deposition in relation to the bifurcation, which is best visualized in panels B and E.
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Figure 2.9. Ex vivo imaging frames and histopathology of identical cross-sections at the approximate
negative region of interest. A) On grayscale IVUS, we did not observe any disease. B) On NIRS-IVUS, we
did not detect any presence of lipid. C) On IVPA-US image (merged shown) we did not observe and lipid
signal. D) We calculated the area with strong lipid signal on IVPA as 0.62 mm2. E, F) Movat’s pentachrome
stained section, showing healthy artery morphology.

Discussion
In this study, we have shown that our IVPA-US imaging system and collinear catheter
design is capable of depth-resolved assessment of lipid content in both fixed and fresh
carotid arteries from Ossabaw swine on atherogenic diet. On IVPA-US imaging of the
fixed carotid artery specimen, we found strong and unambiguous lipid signal on the PA
channel within the borders of the internal elastic lamina, as identified on the US channel.
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It is only by virtue of the depth resolution and uniform overlap of two modalities that we
were able to localize the lipid core. Our imaging results provided us with sufficient
structural (i.e. fibrous and eccentric by US channel) and compositional (i.e lipid by PA
channel) information to posit the observed plaque to be a fibrofatty phenotype [23]. We,
however, were not able to conclude this lipid-rich plaque phenotype definitively. The main
limitation in the investigation of this sample was the ambiguity in of the ORO stained
histology, in which there was an artifact due to tissue tearing [301]. While this is common
when cryosectioning soft lipid-laden plaques, it is not acceptable for device validation.
Despite this overarching limitation in this data set, it provided us invaluable data for proofof-concept capability of our platform. Just as vital was the feedback from this investigation
in refinement of our fresh carotid artery imaging protocol.
In our fresh carotid artery imaging experiments, we performed the first comparison to
commercially available intravascular tools, including NIRS-IVUS which is the only
clinically-approved dual-modality catheter for lipid detection. On traditional angiography
and grayscale IVUS imaging, the early atherosclerotic changes present in the Ossabaw
swine were unidentifiable and assumed to be disease-free—a gross misclassification. It
was only with the addition of a second modality to IVUS that we were able to observe
pathology at the carotid bifurcation, confirming the value of hybrid imaging [58, 273]. This
site of disease development is in accordance with our understanding that atherosclerosis
often develops preferentially at branch points with turbulent flow [302-305]. We found that
our IVPA-US imaging catheter produces comparable results to NIRS-IVUS. The
agreement between the modalities is nontrivial, particularly because NIRS-IVUS imaging
has been exhaustively validated for lipid detection previously [108, 110, 205, 292].
Furthermore, comparison of the results from both modalities to gold-standard
histopathology suggests that IVPA-US results correlate better than NIRS-IVUS results. As
IVPA-US imaging provides the depth-resolution lacking in NIRS-IVUS, we were able to
quantify the cross-sectional lipid core area, which agreed with the area calculated on
histology (0.62 mm2 vs. 0.70 mm2). Additionally, we localized the lipid core as superficial,
confirmed by histology. Conversely, NIRS-IVUS imaging overestimated lipid deposition
at the positive region of interest, showing high probability of lipid spatially distributed
from 2 to 4 o’clock and a very high maxLCBI4mm of 469. This disagreement with histology
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further illustrates the need for depth-resolved lipid core imaging and head-to-head
comparative study.
The major limitation in this investigation was the limited sample size. Although we
imaged 16 carotid arteries, 15 data sets were not useable. This was due to either inability
to identify anatomic landmarks on US for alignment of modalities or lack of any lipidpositive regions of interest. We hypothesize that the low levels of disease may be attributed
to the young age that animals were started on their diet (approximately 6 months) during
which time they are more resistant to vascular changes, even in the presence of elevated
cholesterol [306]. Nonetheless, this provided samples in which we were able to exhibit
sensitivity for pre-clinical levels of lipid content. Furthermore, we acknowledge that US
resolution of our collinear catheter was limited in deep-field, attributed to the multiple
reflection surfaces in the design. While this did not affect interpretation of the vessel wall
in which three-layer appearance was identifiable, deep-field structures such as branches
were difficult to identify consistently. Lastly, our IVPA-US imaging catheter lacked a
protective sheath, precluding us from performing pressure-perfused imaging. In NIRSIVUS, we did perform pressure-perfused imaging with PBS. However, the automated
analysis algorithms are optimized for imaging through blood which attenuates
spectroscopic signal, which may explain some overestimation by this modality [108, 197].
In the future, we intend to extend our study to include a robust data set of plaque phenotypes
form early to advanced lesions.
Conclusions and Outlook
Taken together, we have shown proof-of-concept demonstration of our IVPA-US
imaging catheter system and collinear catheter design for lipid content detection in a fixed
carotid artery with atherosclerotic disease. Furthermore, we have shown validation of our
catheter-based system for additional depth-resolved detection and quantification of
preclinical atherosclerosis in a fresh carotid artery. This was conducted via systematic
comparison to gold-standard histopathology and NIRS-IVUS at identical artery segments.
Furthermore, without the additional information gained from a lipid-specific modality, one
could perceive this artery from a dyslipidemic swine as disease-free with the use of
grayscale IVUS alone – a gross misclassification.
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Ultimately, lipid-specific imaging with depth resolution will advance understanding of
the pathogenesis and prevalence of vulnerable plaque rupture and development of
preventative and interventional therapies [55]. Particularly, quantitative localization of
early atherosclerosis will permit longitudinal studies to monitor progression to the most
vulnerable plaque phenotype: TCFA [58, 59, 272, 273]. We currently do not know the
prevalence of TCFAs in the general population and precisely how prone to rupture and
subsequent MACE they are [275, 288]. Despite the advances made, our understanding of
plaque rupture and progression to ACS is primarily based on post-mortem studies from the
late 1990s to early 2000s [21, 33, 40, 286, 307]. The only in vivo evidence we have is from
the PROSPECT study, which reported only 4.4% of TCFAs, as defined by VH-IVUS,
caused MACE during 3.4-year follow-up period. This is low, especially considering the
study enrollees were already high-risk patients [100]. This observation and lack of sound
evidence supporting the vulnerable plaque hypothesis has led to recent challenges to the
concept [276, 280, 284-287, 308, 309]. However, this challenge to vulnerable plaque
hypothesis and imaging is contentious, as the absence of evidence primarily stems from
the lack of a valid in vivo modality to study this process in the general population. With
depth-resolved localization of lipid-rich necrotic cores, a hallmark of TCFAs, IVPA-US
imaging has the potential to provide powerful information in filling this void.
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3. ASSESSMENT OF LIPID CORE PLAQUES IN HUMAN
CORONARY ARTERIES: AN EX VIVO VALIDATION STUDY
Rationale
The present study aims to demonstrate the capability of real-time intravascular
photoacoustic-ultrasound (IVPA-US) imaging catheter for depth-resolved assessment of
lipid core plaques in fixed and fresh coronary artery specimens from post-mortem and
explanted human hearts. Similar to our previous study in a swine model, we compare
IVPA-US imaging results to gold-standard histopathology and near-infrared spectroscopyintravascular ultrasound (NIRS-IVUS), in order to establish agreement between competing
modalities and also highlight the relative advantages of each. Although large animal
models can provide the advantage of systematic control of vascular pathology, it remains
difficult recapitulate the advanced and complex atheromatous plaques of humans [310314]. Development of humanlike lesions have been shown to be possible, but require
significant and long-term infrastructure (e.g. financial and personnel) towards animal
maintenance for genetic or diet-induced disease, which still is not always predictable in
terms of location and severity [147, 315]. Thus, the ex vivo interrogation of fresh,
atherosclerotic human coronary arteries is imperative in evaluating the capability to detect
lesions that resemble what is encountered in clinical practice. Portions of the work
presented in this chapter have been published previously in Scientific Reports or under
review for publication, and have been intentionally reproduced here with permission [254,
316].
Materials and Methods
3.2.1

IVPA-US Imaging System and Data Acquisition

A Nd:YAG pumped OPO (Nanjing Institute of Advanced Laser Technology) emitting
at a wavelength of 1730 nm, pulse width of 10-11 ns, and repetition rate of 2 kHz was used
as the optical excitation source for photoacoustic imaging work presented in this chapter.
Light was coupled to the catheter via a multimode fiber (MMF) (FG365LEC, Thorlabs,
Inc.) and a custom-built fiber-optical rotary joint, which allowed for efficient optical
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coupling and radiofrequency signal transmission at high rotational speeds. The pulse
energy at the catheter probe tip was controlled to 80-100 µJ, corresponding to an energy
density of approximately 40-50 mJ/cm2 at the tissue surface, below the 1.0 J/cm2 ANSI
safety standard for skin at 1.7 µm [298]. Video-rate rotational imaging and longitudinal
pullback were enabled by a rotatory step motor (X-NMS17C-E01, Zaber Technologies,
Inc., Vancouver, BC) and linear stage (X-LRM100A, Zaber Tchnologies, Inc.) Sequential
IVPA and IVUS signals were generated and detected with a 5-8 µs time delay (Model 9512,
Quantum Composers, Inc., Bozeman, MT) and a single-element transducer (0.5 x 0.6 x 0.2
mm3, 42 MHz, 50% bandwidth; Blatek, Inc.). Signals were amplified by a factor of 39 dB
and acquired digitally via a data acquisition card (ATS9350 PCI express digitizer,
AlazerTech) with 12-bit digitization , 500 MS/s sampling rate, and data throughput of 1600
MB/s. The digitized data was processed and displayed in real-time by the computer with
LabView-based algorithm (LabVIEW, National Instruments, Austin, TX) and intuitive
graphic user interface. A differentiated A-line strategy was used, in which there is a
mismatch between the A-lines collected for IVPA and IVUS. This novel strategy
overcomes the main limitation to high-speed IVPA-US imaging: laser pulse repetition rate.
In this strategy, A-lines are reciprocal with imaging speed and A-lines per IVUS images
two times that of IVPA images. In this work, we present data collected at 16 fps (IVUS:
250 A-lines, IVPA: 125 A-lines) and 4 fps (IVUS: 1000 A-lines, IVPA: 500 A-lines). All
components of this system were installed on a single cart and made portable. Further
characterization of imaging system performance, description of the system architecture,
and differentiated A-line strategy are found in detail in work previously published by our
group [254].
In this work, we used two catheter designs: collinear and quasi-collinear. Collinear
catheter design was the similar as described previously in Chapter 2.2.1, with the key
difference being an overall smaller catheter diameter of 1 mm. This was possible by use of
a smaller rod mirror (diameter: 365 µm), fabricated from MMF polished to 45o and coated
with gold to provide 99% optical reflection and damage threshold up to 1 J/cm2. The
catheter housing was 3D printed (Proto Labs, Inc., Maple Plain, MN) with micro-resolution
stereolithography and maintained alignment of components. This design was used for fixed
artery imaging and was not enclosed in a sheath.
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For fresh artery imaging, we use a quasi-collinear catheter design that varied slightly
from the design presented in Chapter 2.2.1 and above. In this design, the MMF was not
polished to 45o. Instead, acoustic delivery was directed to the artery wall without any
reflection via tilting of the US transducer at a 10o angle. This angle maximized the overlap
between acoustic and optical paths over an estimated depth of 0.6-6 mm, calculated by
geometrical calculation that assumed a 6o divergence angle for the optical beam and 3o for
the US wave. This design was enclosed in a protective polyurethane sheath (outer diameter:
1.6 mm), due to its low optical absorption at 1.7 µm and low acoustic impedance. The
IVPA-US quasi-collinear catheter system demonstrated axial resolution from 85-100 μm
and lateral resolution 170-450 μm from at depths ranging from 1.4-4.6 mm, as measured
by a 7 μm-diameter carbon fiber in deuterium oxide (D2O) as a standard. The portable
IVPA-US imaging system and catheter designs are summarized in Figure 3.1.
3.2.2

Human Tissue Recovery and Preparation

Fresh human hearts were recovered post-mortem or from individuals undergoing
transplant surgery, within 24 hours of death or explant. Arteries were maintained in EH
storage solution at 4 oC and imaged within 48 hours of tissue recovery. The right coronary
artery was excised, retaining one inch of surrounding myocardium to maintain vessel
structure. The ostium was cannulated with a shortened 6-8 Fr introducer sheath and side
branches and the distal end of the artery were ligated with suture for pressure-perfusion.
For the artery imaged after fixation, 10% formalin was used to pressure-fix the artery for
20 minutes at 25 mL/min and placed in formalin for 24 to 48 hours. For the artery imaged
fresh, perfusion and artery anatomy were observed by ex vivo angiography with contrast.
This protocol was approved by the Indiana University School of Medicine Institutional
Review Board by exemption.
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Figure 3.1. IVPA system architecture and catheter designs. A) Schematic of the IVPA system. Optical and acoustic pulses are delivered via multimode fiber
and electrical wire. Generated signals are acquired and display in real-time on a computer. Rotational and linear translational are enabled by a motorized carriage
system. The catheter sheath is flushed via Luer-slip connector. B) Image of the portable system. Major components: 1, oscilloscope; 2, fiber-optic rotary joint; 3,
IVPA-US catheter; 4, delay generator; 5, US pulser/receiver; 6, Laser source; 7, Laser controller; 8, Mobile cart; 9, Laser chiller; 10, PC and DAQ card; 11, Monitor.
C) Collinear catheter design, used without a sheath for fixed human coronary artery imaging. D, E) Quasi-collinear design, in which angling of the transducer and
reduction of reflection surfaces maintained optical and acoustic co-registration and improved US resolution. This design was used for fresh human coronary artery
imaging with a polyurethane sheath. F) Photograph of the IVPA-US catheter, with sheath. Adapted from Hui et al. (Sci Rep, 2017) and Cao et al. (Sci Rep, 2018).

48
3.2.3

Ex Vivo Imaging and Histology

The coronary artery imaged fresh was pinned in a Sylgard® 184 Silicone Elastomer
(Dow Corning, Corp.) tray and submerged in 1X PBS at room temperature and was
perfused to physiologic pressures during imaging. A 3.2 Fr, 40 MHz NIRS-IVUS catheter
(TVC Insight, Infraredx, Inc.) was introduced into the coronary artery via hemostatic
introducer sheath and advanced to a maximal distal point, where the artery was ligated
(approximately 70 mm distal to the introducer sheath). The vessel was perfused during an
automated pullback at 0.5 mm/s and imaging speed of 16 fps. Pullback was complete when
the imaging catheter retreated into the introducer sheath. The procedure was repeated using
our 4.8 Fr, 42 MHz IVPA-US quasi-collinear catheter with sheath, flushed with D2O, at a
pullback speed of 0.25 mm/s and 4 fps imaging speed. Alignment of pullbacks from
different modalities was conducted via identification of fiduciary branch points and the
introducer sheath, with angiographic aid.
Imaging of the fixed coronary artery specimen followed a similar protocol, with the
following alterations. IVPA-US imaging was performed using a collinear catheter without
a surrounding sheath. We did not pressure-perfuse the vessel during imaging due to the
lack of sheath and maintenance of vessel structure after pressure-fixation. No NIRS-IVUS
imaging was performed, due to inability to advance the catheter into the vessel. The artery
was pinned in a Sylgard tray and submerged in D2O. Next, our IVPA-US catheter was
advanced distally to a point of resistance (due to tortuous anatomy and rigid structure after
fixation). We performed an automated pullback at 0.2 mm/s and 1 fps imaging speed of
the entire segment. Next, we identified a positive region of interest (an area with strong
signal in the IVPA channel) and repeated imaging at this location at 16 fps. This region
was marked with suture for accurate histological sectioning.
The fresh coronary artery were pressure-fixed using 10% formalin with a large-barrel
syringe at approximately 25 mL/min for 30 min and placed in formalin for >24 hours.
Fixed arteries were then grossly sectioned in 2.5 to 4 mm segments. Next, segments were
paraffin embedded, thin sectioned, and stained with H&E and Movat’s pentachrome stain.
For segments identified as positive of region interests, multiple thin sections were cut
serially at 250 µm intervals. Lipid pools were defined as morphologically distinct empty
and/or clear, granular, mostly anucleate spaces, defined as the light-microscopic
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characteristics of lipid gruel [202, 300]. Lipid area was calculated using ImageJ (1.48v,
National Institutes of Health, USA) software.
3.2.4

IVPA-US and NIRS-IVUS Quantitative Analysis

IVPA-US imaging data were post-processed to identify noise, and photoacoustic pixels
greater than 4 times the background noise were counted per cross-sectional frame to
calculate lipid area (Fig. 3.2). Pullback segments in which the introducer sheath was
present were excluded from analysis. Lipid core volume was calculated per lesion within
a 4-mm segment by identifying appropriate depth and angle boundaries within which pixels
were counted. All lipid pixel area measurements were calculated using MATLAB software
(MathWorks, Inc., Natwick MA).
The NIRS-IVUS TVC Imaging System was used to generate 2D chemograms
representing probability of the presence of lipid by a yellow color, with longitudinal
pullback position on the x-axis and circumferential position on the y-axis. As NIRS spectral
depth is 1 mm or less, lipid area was estimated by measuring the yellow-colored regions
on the chemograms via segmentation using ImageJ. The maxLCBI4mm was also calculated
by the system.
Calcification was measured by IVUS and defined as strong echogenicity with acoustic
shadowing. The total length was calculated as continuous frames in which calcification
was present. Maximum arc of calcification was calculated as the largest angle of acoustic
shadowing within the total length, with each ray following the acoustic shadowing and the
vertex at the center of the vessel lumen [317-320]. All IVUS analysis was performed using
ImageJ software.
Data are described as mean ± SEM. Statistical significance defined as p<0.05. Unpaired,
two-tailed Student’s t-tests were used as appropriate using GraphPad Prism statistical
software (GraphPad Software, Inc., La Jolla, CA).
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Figure 3.2. Lipid area calculation from IVPA data. A) Cross-sectional photoacoustic image, reconstructed
from raw data with indiscriminate noise, catheter noise, and sheath noise. B) Cross-sectional binary lipid map
after a threshold of 4 times the background noise level was applied (white denotes presence of lipid). The
total lipid area in this example was calculated from the sum of white pixels (156.25 µm2/pixel; total area =
0.15 mm2).

Results
3.3.1

IVPA-US Imaging of a Fixed Human Coronary Artery

We imaged a formalin-fixed right coronary artery (RCA) from an obese 44-year old
Caucasian male (BMI=32) with a past medical history of tobacco and alcohol use,
hypertension, and previous MI. At the time of recovery, pericardial tamponade, left
ventricular hypertrophy, and extensive valvular calcification were observed (Fig. 3.3A).
The cause of death was reported as atherosclerotic hypertensive cardiovascular disease.
We performed IVPA-US imaging of the segment of interest using a collinear catheter
without sheath in a D2O environment at 16 fps imaging speed (Fig. 3.3B). IVUS, IVPA,
and merged cross-sectional images are shown in Figure 3.4A-C. On IVUS (Fig. 3.4A), we
observed a lesion encroaching the lumen at 1 to 3 o’clock. On IVPA (Fig. 3.4B), we
identified two areas with strong PA signal at 1 to 3 o’clock and 8 o’clock, suggesting the
presence of lipid-rich cores. On merged imaging (Fig. 3.4C), we used IVUS findings to
localize these suspected lipid cores. The first suspected core was shown to be superficial
in the eccentric lesion encroaching the lumen, with a total lipid area of 0.21 mm2. The
second suspected core was shown to be superficial, thin, and within a concentric fibrous
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lesion, as evidenced by the strong echogenicity observed on IVUS [321]. The total lipid
area was measured as 0.07 mm2. On Movat’s pentachrome-stained histopathology (Fig.
3.4D), we confirmed the presence of an advanced fibroatheroma with pathologic features
that match imaging results. First, we observed a concentric fibroatheroma with a raised
area, showing identical lumen morphology as seen on imaging. Secondly, we observed two
lipid-rich necrotic cores at locations and sizes that correlate with imaging results (Fig. 3.4EG). On histopathology, lipid-rich necrotic cores were identified as acellular areas with
macrophage infiltration to the core and cap, devoid of extracellular matrix, lack of specific
staining, cholesterol clefts, and an overlying fibrous cap [15, 23, 28, 41, 139]. We measured
necrotic core areas of 0.59 mm2 and 0.35 mm2 for the lesions at 2 to 3 o’clock and 9 to 11
o’clock, respectively. Fibrous cap thickness overlying both cores were approximately 200
µm at the thinnest region. Additionally, we noted other pathologic features that indicate
the advanced thick-cap fibroatheroma phenotype such as medial thinning and
microcalcifications, a marker of inflammation and instability [322, 323]. Lastly, we
observed intraplaque hemorrhage as another marker of vulnerability, possibly from
neovascularization (Fig. 3.4H) [324, 325]. IVPA-US imaging results and corresponding
histopathology were consistent with the reported past medical history of the donor.

Figure 3.3. Post-mortem human heart and right coronary artery gross image. A) Gross image of the
human heart, with the aorta (Ao) and hypertrophic left ventricle (LV) shown in the inset. B) Excised right
coronary artery, with the approximate region of interest imaged by IVPA-US highlighted (green, arrowhead).
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Figure 3.4. IVPA-US imaging results and corresponding histopathology. A) IVUS cross-sectional image,
showing an eccentric raised lesion encroaching the lumen at 1-3 o’clock. B) IVPA image showing lipid (red).
C) Merged IVPA-US image shows a strong area of PA signal in relation to the lumen as seen on IVUS
(traced), suggesting the presence of two lipid-rich cores (boxes). D) Movat’s pentachrome stained histology
section, with lumen border traced and key features outlined in boxes; from left: thin lipid-rich necrotic core
(G), intraplaque hemorrhage, large lipid-rich necrotic core (E,F). Also shown are microcalcifications stained
black (arrow) and medial thinning (arrowhead). E, F) Magnified views of the large lipid-rich necrotic core
(arrow) with cholesterol clefts (*) and an overlying thick fibrous cap with macrophage infiltration
(arrowhead). G) Magnified view of the second lipid-rich necrotic core, thin in morphology with a thick
fibrous cap. H) Non-communicating intraplaque hemorrhage, consistent with neovascularization. Horizontal
and vertical axis tracings in A-C are 1 mm apart. Adapted from Hui et al. (Sci Rep, 2017).
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3.3.2

Comparative IVPA-US and NIRS-IVUS Imaging of a Fresh Human
Coronary Artery

We imaged a fresh human RCA harvested from a 59-year old male undergoing
transplant surgery. The patient had coronary heart disease risk factors of obesity
(BMI=31), smoking, past history of hypertension, and age. Additionally, the patient
had past medical history of heart failure with reduced ejection fraction and
paroxysmal atrial fibrillation. On ex vivo imaging of the diseased artery, we identified
two advanced fibroatheromas with calcification on both IVPA-US and NIRS-IVUS
(Fig. 3.5). Comparison between modalities was conducted with angiographic aid and
identification of anatomical and physical landmarks, such as fiduciary side branches
and the introducer sheath. We defined the atheroma proximal to the introducer sheath
as Lesion 1 and the distal atheroma as Lesion 2 (Fig. 3.6). On both hybrid modalities,
calcification was evident on ultrasound by strong echogenicity with acoustic
shadowing. Furthermore, lipid was present as indicated by yellow color on the
circumferential chemogram by NIRS and red color on co-registered cross-sectional
images by IVPA-US. Characterization of the atherosclerotic features in both lesions
were confirmed by histopathology, with calcified lipid pool areas measuring 0.42
mm2 and 1.36 mm2 for Lesions 1 and 2, respectively.
On IVPA imaging, we calculated the average cross-sectional lipid area within a 4-mm
segment for both lesions. Lesion 1 had an average lipid area of 0.15 ± 0.004 mm2 (Range:
0.08 – 0.24) and Lesion 2 had an average lipid area of 0.40 ± 0.03 mm2 (Range: 0.04 –
1.04). Particularly, Lesion 2, within the measured 4-mm segment, had a significantly
greater average lipid area than the remaining length of artery (0.40 mm2 vs. 0.26 mm2;
p<0.0001). We further measured the total lipid area within a 4-mm segment for each lesion
(Lesion 1: 9.57 mm2, Lesion 2: 25.95 mm2). Lastly, depth resolution and co-registered
imaging allowed us to identify the contiguous lipid areas adjacent to calcification as the
plaque lipid core and calculated the volumes as 0.11 mm3 and 0.25 mm3 for Lesions 1 and
2, respectively. Relation of the plaque lipid core to calcification and the lumen border is
further illustrated by three-dimensional reconstruction of the 4-mm segments (Fig. 3.6C,
D). These quantifications were in agreement with histopathology and similar measures
made by NIRS-IVUS imaging.
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On NIRS-IVUS, we found Lesion 2 to have a high maxLCBI4mm value of 326,
consistent with the large lipid area and core volume measured by IVPA-US. No
maxLCBI4mm was calculated for Lesion 1 due to lack of sufficient spectrally valid pixels.
Using the generated chemogram, we approximated lipid areas as 5.22 mm2 for Lesion 1
and 26.38 mm2 for Lesions 2, comparable to the values measured by IVPA-US.
Comparison of NIRS chemogram and IVPA fold-out map of PA signal intensity are
illustrated in Figure 36, with the two lesion 4-mm segments highlighted. At areas where
lipid was detected by IVPA, in the absence of an atheroma, PA signal was localized to arise
from perivascular adipose tissue (PVAT) (Fig. 3.6E). No lipid was detected at identical
regions by NIRS (Fig. 3.6F).
In addition, we characterized the calcification in both lesions by measuring the total
length and maximal arc of calcification, as shown in Table 3.1. Both IVPA-US and NIRSIVUS systems showed similar values, demonstrating comparable US resolution for the
identification of calcification. Comparative imaging by multiple modalities and goldstandard histopathology confirm that depth-resolved IVPA-US has the capability to
quantify and localize plaque lipid cores with calcification.
Table 3.1. Comparison of lesion characteristics from ex vivo imaging of a human right coronary artery
by NIRS-IVUS and IVPA-US.

Lesion 1
(Proximal)

Lesion 2
(Distal)

NIRS-IVUS Measured Lesion Characteristics
maxLCBI4mm

N/A

326

Total Lipid Area (mm2 )

5.22

26.38

3.1

2.0

46.2

66.7

0.15 ± 0.004

0.40 ± 0.03

Total Lipid Area4mm (mm )

9.57

25.95

Lesion Lipid Core Volume (mm3 )

0.11

0.25

Total Calcified Length (mm)

3.4

2.4

Maximum Arc of Calcification (o)

58.1

66.4

Total Calcified Length (mm)
o

Maximum Arc of Calcification ( )
IVPA-US Measured Lesion Characteristics
Average Lipid Area4mm (mm2 )
2

Figure 3.5. Correlation between modalities in a fresh human coronary artery. A) Ex vivo angiogram of the artery, in which the sheath (I), side branches (II,
V), and lesions locations (III, IV) are identified. Location III refers to Lesion 1 and location IV to Lesion 2. B, C) Corresponding cross-sectional still frames are
shown from NIRS-IVUS (B) in which lipid is shown with yellow and from IVPA-US (C) in which lipid is represented by red. Notable side branches are
indicated by arrowheads and calcification by arrows. D) Movat’s pentachrome stained histological sections of lipid core lesions (*) with calcification (arrows).
Horizontal and vertical axis tracings are 1 mm apart.
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Figure 3.6. Aligned chemogram comparison for human coronary artery imaging and 3D reconstructions of fibroatheromas imaged by IVPA-US. A, B)
At the highlighted 4-mm lesion segments, both modalities show lipid either by yellow color on the NIRS chemogram or red color on the IVPA fold-out map. C,
D) Merged reconstructions for Lesion 1 (C) and Lesion 2 (D), in which the US channel is depicted in grayscale and PA channel in red. Calcification has been traced
with a dash line and lipid core identified with an arrowhead. Both reconstructions are 4-mm in length and correspond to the segments highlighted in A and B. E)
IVPA-US still frame image at a proximal portion of the artery, at which no lesion was observed and detected lipid (red) was localized as perivascular adipose tissue
(arrows). F) NIRS-IVUS still frame at the same region, with no lipid detected. Horizontal and vertical axis tracings are 1 mm apart.
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Discussion
In this study, we have demonstrated that our IVPA-US imaging system, with collinear
and quasi-collinear catheter designs, can detect the lipid rich-cores with depth-resolution,
as validated against gold-standard histopathology.
On IVPA-US imaging of a fixed atherosclerotic coronary artery, we identified two lipid
cores by strong and unambiguous signal on IVPA. Furthermore, depth resolution allowed
us to localize these plaque cores as superficial and quantify the size and shape. The larger
plaque core (0.21 mm2) was located close to the lumen border within a raised eccentric
lesion. The smaller plaque core (0.07 mm2) was within a fibrous area, as evidenced by the
strong echogenicity on IVUS. Our findings were confirmed by correlation of plaque
features and lumen morphology on histopathology. We characterized the plaque as an
advanced fibroatheroma, with two lipid-rich necrotic cores that correlate in size and
location to our imaging findings. The discrepancy in core areas calculated on histology
versus IVPA-US was expected, as imaging identified areas of lipid with chemicalselectivity and on histology we calculated areas of the total plaque core. Although lipidrich, plaque cores in advanced lesions have heterogeneity that also includes calcification,
inflammatory infiltrate, and apoptotic cellular debris which are not apparent on imaging.
Both IVPA and IVUS axial resolutions were insufficient to properly assess fibrous cap
thickness, but with improvements this could be possible via post hoc calculation of the
distance between the lumen border (by US) and lipid core (PA). Additionally, we identified
intraplaque hemorrhage on histopathology, but not on IVPA-US imaging. This provides
evidence of lipid-specificity, but demonstrates limitation in identifying multiple
determinants of instability. In the future, identification of other components via spectral
analysis, such as cholesterol crystals, may serve to provide information regarding plaque
vulnerability as a surrogate marker [261]. Lastly, this investigation achieved milestones
towards clinical translation. We provided the first demonstration of IVPA-US imaging at
video-rate imaging speed (16 fps), comparable to commercial systems and sufficient to
suppress artifacts of cardiac motion. In addition, we integrated our system with a real-time
display interface. This nontrivial feature provided the operator with feedback necessary to
adjust parameters (i.e. pulse energy, amplification, imaging and pullback speeds) and
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catheter position based on the processed and displayed IVPA and IVUS images. The
overarching limitations of our study include the lack of a protective sheath, imaging of a
post-mortem specimen in which plaque features may be altered due to fixation, and
demonstration in an ideal D2O environment that does not mimic in vivo challenges [326].
These have been addressed subsequently in our fresh artery imaging experiment.
In our study of a fresh specimen, we provide the first comparison of IVPA-US to NIRSIVUS for the detection of lipid core plaques. As the only approved device for imaging lipid
rich plaques, NIRS-IVUS undoubtedly has great promise in clinical practice. Yet, lack of
depth resolution limits quantitative imaging of lipid and relies upon LCBI as a derived
measure to distinguish between high- and low-risk plaques, for which the optimal cutoffs
are still undetermined [216, 217, 221, 222] . In this comparative study, we have shown
agreement between modalities in detection of lipid at matching sites within the RCA, using
IVUS-defined features such as calcification and branches as fiduciary landmarks to align
pullbacks. These findings were confirmed on histopathology. Furthermore, we highlighted
the value of depth resolution in lipid assessment. We have demonstrated the capability of
IVPA-US to differentiate between superficial and deep lipid, i.e. lipid within a plaque core
versus PVAT. We showed localization of lipid cores in relation to plaque features such as
calcification and quantification of plaque volume. Volumetric quantification permits more
meaningful longitudinal studies monitoring plaque changes. Furthermore, alterations in
plaque morphology and composition would be more apparent with visualization of core
dimensions and relation to other plaque components. This would aid in elucidation of the
prevalence and mechanisms of TCFA development, stability, and rupture as discussed
previously (see Chapter 2.4) [275, 327] . Additionally, in disease-free segments with lipid
signal, we localized signals to arise from PVAT, a key mediator of atherogenesis [242, 255,
267-269]. This was not apparent on NIRS-IVUS imaging at the same region.
Lastly, we demonstrated functionality of an outer polyurethane sheath with minimal PA
and US signal attenuation. This materials engineering feat fulfilled a prerequisite for in
vivo imaging. A proper sheath is a practical necessity in order to provide a mechanical
barrier to prevent bleeding at the site of catheter introduction in vivo (e.g. femoral artery),
in addition to preventing damage and impingement of the rotating torque coil during
pullback. Furthermore, a sheath protects the vascular endothelium from damage as the
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catheter tip rotates and retreats at high-speed within the intravascular space during pullback.
Although signal loss was minimal, there is room for improvement with the use of thinner
materials and post-processing removal of PA artifacts arising from the sheath. We also
demonstrated improved US resolution with our quasi-collinear catheter design and
differential gain applied radially, i.e. higher gain at larger depths. Direct interrogation of
the vessel wall without reflection allowed us to identify deep-field structures such as side
branches and also characterize calcification with similar resolution to commercial devices.
Our study was limited by a small sample size that did not include a range of atherosclerotic
plaque phenotypes. Thus, we were unable to calibrate our thresholding algorithm for lipid
area to match histopathological lipid core area and PVAT thickness. We intend to build a
larger calibration data set to address this limitation.
Conclusions and Outlook
Despite advances in creating humanlike atherosclerosis in animal models, there is no
substitute for imaging true complex atherosclerotic plaques from humans. Here, we provide
ex vivo validation of IVPA-US for the detection of advanced lesions with depth resolution
to localize and quantify lipid cores, as confirmed by histology. Furthermore, as modalities
for lipid imaging advance in capability and combination, comparison will be instrumental
in determining the relative advantages and disadvantages. To our knowledge, this is the
first head-to-head study of IVPA-US against NIRS-IVUS for characterization of postmortem human coronary atherosclerosis. We have shown agreement between modalities
and the value of depth resolution. Lastly, this study introduced key technical innovations
towards clinical translation: real-time imaging at video-rate speeds, improvement of US
resolution, and incorporation of a sheath.
Understanding lipid core dimensions would provide powerful information in
longitudinal studies of the efficacy of pharmaceutical therapies, lifestyle modifications, and
public policy measures [309]. Furthermore, early identification of plaques with superficial
lipid cores would allow cardiologists to implement preventive measures such as aggressive
medical therapy or placement of vascular scaffolds—both with the intent to promote plaque
stabilization [277-279, 283]. Thus, IVPA-US imaging could open opportunities beyond the
reach of other intervascular imaging tools [57, 58, 61].
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4. IN VIVO ASSSESSMENT OF IVPA-US IMAGING IN OSSABAW
SWINE WITH METABOLIC SYNDROME
Rationale
Ex vivo studies for intravascular imaging device validation are natural prerequisites for
clinical translation. These studies provide the basis for iterative refinement of catheter
design, calibration of classification algorithms, and demonstration of predictive accuracy,
all in a controlled environment. To simulate in vivo conditions, researchers have
incorporated pulsatile flow pumps for perfusion of whole blood at physiologic pressure
and temperature [203]. Despite these efforts, there are many in vivo parameters that are not
recapitulated well or at all ex vivo. Vascular motion, hemodynamics, and physiologic noise
are all better studied in vivo. Furthermore, evaluation of safety and robustness of the device
and procedure are best conducted in vivo, where there is less control of the environment.
Thus, parallel in vivo testing in preclinical models can provide valuable information
guiding catheter enhancement and validation. In this work, we present in vivo evaluation
of our IVPA-US imaging catheter in a systematic comparative study against NIRS-IVUS.
We use both modalities to investigate sensitivity to detect early atherosclerosis in Ossabaw
miniature swine with metabolic syndrome (MetS) versus lean control swine. We further
use this investigation as an opportunity to evaluate the safety, performance, and
reproducibility of our device for in vivo imaging. The work presented in this chapter is
currently under review for publication.
Materials and Methods
4.2.1

IVPA-US Imaging System and Data Acquisition

The portable high-speed IVPA-US imaging system used in this work has been described
in detail previously (see Chapter 3.2.1). Briefly, a nanosecond Nd:YAG pumped optical
parametric oscillator excitation laser source emitting at 1.7 µm with a 2 kHz repetition rate
was used for photoacoustic excitation. A collinear catheter with a 42 MHz transducer was
used for all swine imaging presented in this chapter. The catheter was fully enclosed within
a protective sheath composed of polyurethane and had an outer diameter of 1.6 mm. For
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all IVPA-US imaging, the catheter sheath was flushed with D2O due to decreased optical
absorption compared to H2O.
4.2.2

Animal Care and Use

Ossabaw miniature swine (n=3) were maintained to meet the characteristics of MetS for
eight months, seven of which they were fed a hypercaloric, atherogenic diet (1 kg/day),
and aged approximately 16 months at the time of euthanasia. For a lean control, a subset
of swine (n=2) were fed a standard chow diet (0.7 kg/day). Swine were individually housed
with free access to water. Metabolic data including body weight, blood pressure, serum
chemistry, and plasma lipids were collected to confirm development of MetS and
dyslipidemia. Development of MetS and CAD in this naturally progressive animal model
of human disease has been characterized in previous work (e.g. [294, 296, 328]).
Anesthesia was induced via intramuscular injection of telazol (5-6 mg/kg) and xylazine
(2.2 mg/kg), and maintained with 2-4% isoflurane mixed with 100% oxygen. The
isoflurane level was adjusted during the in vivo procedure to maintain stable
hemodynamics. This protocol was performed according to the Guide for the Care and Use
of Laboratory Animals and approved by the Indiana University School of Medicine Animal
Care and Use Committee [299].
4.2.3

In Vivo Imaging: Angiography, Grayscale IVUS, IVPA-US

A shortened 7 Fr introducer sheath was inserted in the right femoral artery of swine and
heparin was administered (50 U/kg). An angiogram with contrast was recorded to visualize
lower limb vascular anatomy. Next, a shortened 7 Fr guiding catheter was advanced to
access the right iliac artery, through which our 4.8 Fr, 42 MHz IVPA-US catheter was
advanced 80 mm distally and two automated pullbacks were recorded at 0.5 mm/s (Fig.
4.1). All in vivo IVPA-US data were collected at 8 fps imaging speed. Following IVPAUS catheter removal, a 3.2 Fr, 45 MHz commercial grayscale IVUS catheter (Revolution,
Volcano, Corp.) was advanced 80 mm distally and a pullback was recorded at 0.5 mm/s.
Angiograms without contrast were recorded after catheter placement and with contrast after
removal. In one lean control animal, right and left iliac arteries were both imaged.
Following imaging, the animals were euthanatized by isoflurane overdose and cardiectomy.
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Figure 4.1. IVPA-US imaging probe and in vivo imaging procedure. A) Schematic of the in vivo procedure,
in which the IVPA-US catheter was advanced 80 mm into the iliac artery of swine. B) Angiogram with
contrast to visualize vascular anatomy. C) Angiogram without contrast to confirm IVPA-US catheter
placement at 80 mm distal to the introducer sheath.

4.2.4

Tissue Recovery and Ex Vivo Imaging

Following euthanasia, the iliac artery was isolated, marked with a suture knot 80 mm
distal to the guiding catheter, and dissected out of the animal with the introducer sheath in
place. Side branches and the distal end were ligated with suture for pressure-perfusion
during ex vivo imaging. The Ossabaw iliac artery segment was pinned in a Sylgard® 184
Silicone Elastomer tray and submerged in 1X PBS, at room temperature. The IVPAUS catheter was advanced to the 80 mm mark and perfused with 1X PBS at
physiologic pressure, during which an automated pullback was recorded at 0.25 mm/s.
All ex vivo IVPA-US data were collected at 4 fps imaging speed. This procedure was
repeated with a 3.2 F, 40 MHz NIRS-IVUS catheter (TVC Insight, Infraredx, Inc.) with a
0.5 mm/s pullback speed.
4.2.5

Imaging and Histology Quantitative Analysis

IVPA-US imaging data were post-processed to reduce noise, and pixels at which PA
intensity was greater than a set threshold were counted per cross-sectional frame to
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calculate lipid area (4 times the background noise for all ex vivo data sets and 5 times the
background noise for all in vivo data sets) (Fig. 3.2). Pullback segments in which the
introducer sheath was present were excluded from analysis. All lipid area measurements
were calculated using MATLAB software (MathWorks, Inc.). Cross-sectional lipid areas
were binned and averaged for correlation analysis between repeated in vivo and ex vivo
pullbacks to assess reproducibility of data. The NIRS-IVUS TVC Imaging System was
used to generate 2D chemograms. The system also generated block chemograms,
representing the artery in 2-mm segments with discrete colorized representation of the
probability of lipid present. We defined blocks colored red as having no lipid present
(P<0.57) and all other colors as having high probability of lipid present (orange:
0.57<P<0.84, tan: 0.84<P<0.98, and yellow: P≥0.98) [206]. Lastly, the total LCBI was
calculated by the system.
Imaged arteries were pressure-fixed using 10% formalin and placed in formalin
overnight. Arteries were then grossly sectioned in 3-4 mm segments. Next, segments were
paraffin embedded, thin sectioned, and stained with H&E and Veorhoeff-Van Gieson
elastin stain. Contralateral control iliac arteries from Ossabaw swine were not pressurefixed. Blinded analysis of maximal intimal thickness was performed using ImageJ to
measure the thickest neointimal layer as determined on Veorhoeff-Van Gieson stained
sections.
All data are described as mean ± SEM. Statistical significance was defined as p<0.05.
Unpaired, two-tailed Student’s t-tests and Pearson’s correlation were used as appropriate
using GraphPad Prism statistical software (GraphPad Software, Inc.).
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Results
4.3.1

Multimodal Imaging of Ossabaw Swine Iliac Arteries

Ossabaw swine on a hypercaloric, atherogenic diet developed the characteristics of
MetS, including significantly greater total cholesterol, triglycerides, blood glucose, and
weight at sacrifice compared to swine in the lean control group (Table 4.1).
Table 4.1. Metabolic Characteristics of Ossabaw Swine

Sex (M/F)
Weight at sacrifice (kg)
Mean weight gain (kg)
Serum chemistry profile
AST (IU/L)
ALT (IU/L)
Alkaline Phosphatase (IU/L)
Bilirubin (mg/dL)
Blood glucose (mg/dL)
Plasma lipids
Cholesterol (mg/dL)
Triglycerides (mg/dL)

Lean
(n = 2)
1/1
50.5 ± 10.5
31.0

MetS
(n = 3)
0/3
95.0 ± 1.5*
58.7 ± 3.0

33 ± 4
24 ± 4
100 ± 13
0.1
62 ± 3

48 ± 7
26 ± 5
85 ± 9
0.3 ± 0.1
167 ± 24*

0.21
0.79
0.39
N/A
0.04

71 ± 12
26 ± 2

465 ± 53*
63 ± 4*

0.01
0.01

P-Value
N/A
0.01
N/A

*p < 0.05 when compared with the lean group.
AST, aspartate aminotransferase; ALT, alanine aminotransferase.

On in vivo and ex vivo iliac artery imaging of both groups, no intimal disease was
observed on all modalities, consistent with histology which showed minimal neointimal
hyperplasia (Fig. 4.2). In the artery segments where lipid signal was present on IVPA-US
imaging, it was localized to the perivascular region and confirmed as perivascular adipose
tissue (PVAT) by histology (Fig. 4.3D). On in vivo IVPA-US imaging, we found the
average cross-sectional lipid area was significantly greater in the iliac arteries of swine
with MetS as compared to lean swine (0.089 ± 0.016 mm2 vs. 0.059 ± 0.001 mm2; p<0.0001)
(Fig. 4.4A). These results were also observed on ex vivo imaging (0.032 ± 0.001 mm2 vs.
0.005 ± 0.0002 mm2; p<0.0001) (Fig. 4.4B). On ex vivo NIRS-IVUS imaging, we found
similar results, as arteries of swine with MetS had significantly more 2-mm block
chemograms with high probability of lipid present than arteries of lean swine (8/117 blocks
with lipid vs. 0/80 blocks with lipid; p=0.02). Additionally, arteries of swine with MetS

66
had a greater average total LCBI than lean swine (50.3 vs. 12.0; p=0.48). However, on
histology, we did not observe any pathologic disease and no significant difference in the
maximal intimal thickness (MetS: 114.2 ± 25.9 µm, Lean: 92.4 ± 15.8 µm; p=0.49) (Fig.
4.4C). Taken together, these results conclude IVPA-US is comparable to NIRS-IVUS in
sensitivity for the detection of increased lipid deposition, even before overt pathology is
apparent on histology. Depth-resolved IVPA-US imaging provides the ability to localize
lipid deposition; more specifically, lipid signals that arise from PVAT.

Figure 4.2. Imaging and histology from a MetS Ossabaw swine iliac artery. A) In vivo IVPA-US still
frame, in which no lipid deposition and a healthy artery morphology (three-layer appearance) was observed.
B) In vivo commercial IVUS still frame, depicting healthy artery morphology, i.e. 3-layer appearance. C) Ex
vivo IVPA-US still frame, in which no lipid deposition and a healthy artery morphology were observed. D)
Ex vivo NIRS-IVUS still frame, in which no lipid deposition and a healthy artery morphology were observed.
E) Verhoeff–Van Gieson stained histological section, showing healthy artery morphology with a small area
of neointimal thickening (inset) on the luminal side of the internal elastic lamina (IEL). M, media; A,
adventitia. Horizontal and vertical axis tracings are 1 mm apart.
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Figure 4.3. In vivo IVPA-US imaging from a MetS Ossabaw swine. A) IVUS channel showing a healthy
three-layer appearance of the iliac artery. B) IVPA channel showing concentric lipid signal (red). C) Merged
composite showing lipid signal localized to the perivascular region. D) Verhoeff–Van Gieson stained
histological section showing abundant perivascular adipose tissue (PVAT). I, intima; M, media; A, adventitia.
Horizontal and vertical axis tracings are 1 mm apart.

Figure 4.4. Average cross-sectional lipid area and maximal intimal thickening in iliac arteries as
determined by IVPA imaging and histology. The average cross-sectional lipid area, as calculated by
photoacoustic signal intensity per frame above a pre-determined threshold, is significantly greater in the iliac
arteries of swine with MetS as compared to lean swine, both by in vivo (A) and ex vivo (B) imaging; ***
p<0.0001; n refers to number of cross-sectional frames analyzed. C) However, there was no significant
difference in the average maximal intimal thickness the iliac arteries of swine with MetS as compared to lean
swine; p=0.49; n refers to number of histological sections analyzed.
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Lastly, we evaluated the safety of the in vivo imaging procedure and reproducibility of
our results. On angiography, we observed no significant vasospasm after IVPA-US
pullback (Fig. 4.5A,B). On histology, we did not observe any significant damage to the
internal elastic lamina of imaged arteries compared to contralateral control arteries (Fig.
4.5C-F). Additionally, in three arteries, we performed repeat in vivo pullbacks and there
was significant correlation of lipid area between pullbacks (p<0.0001 for all data sets) (Fig.
4.6). In a MetS-group swine iliac artery, we further compared lipid area measures from in
vivo pullbacks with ex vivo pullback data and we also found significant correlation (p<0.05
for all data sets) (Fig. 4.7).

Figure 4.5. Sheath performance as measured by post-catheterization vasospasm and endothelial
denudation. A) Pre-IVPA-US angiogram of an artery without catheter intervention. B) Post-IVPA-US
angiogram taken immediately after pullback, showing only mild spasm of the vessel (arrowhead). C)
Verhoeff–Van Gieson stained histological section from an imaged iliac artery, showing an intact internal
elastic lamina (inset, E). D, F) Uncatheterized contralateral iliac artery as control.
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Figure 4.6. Reproducibility of in vivo procedure and results. In three swine, we repeated our pullback
procedure to study the reproducibility of our catheter for lipid area data acquisition. In each animal, we
observe significant correlation between the initial (Pullback 1) and repeat (Pullback 2) data sets. All data sets
were averaged and binned to 50 data points.

Figure 4.7. Correlation plot between in vivo and ex vivo results with 95% confidence ellipsoid. In a swine
with MetS, in which we had minimal noise in two repeat in vivo pullbacks (8 fps imaging speed and 0.5 mm/s
pullback speed) and one ex vivo pullback (4 fps imaging speed and 0.25 mm/s pullback speed), we found
average cross-sectional lipid areas to significantly correlate between all data sets (all p < 0.05). All data sets
were averaged and binned to 50 data points.
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Discussion
Here, we have demonstrated detection of increased lipid deposition in Ossabaw swine
with MetS versus lean swine by in vivo IVPA-US imaging, in agreement with ex vivo
NIRS-IVUS imaging of the same specimens. To our knowledge, this was the first
comparative in vivo IVPA-US imaging investigation for the detection of native
atherosclerosis. We did not observe any significant intimal pathology on all structural
imaging modalities (angiography, commercial IVUS, and IVUS from both hybrid devices)
and histology in both MetS and lean animals. Thus, we conclude agreement in negative
control samples. However, on compositional modalities, i.e. NIRS and IVPA, we observed
inter-group differences in arterial lipid content. MetS-group swine with dyslipidemia
exhibited significantly greater detected lipid than lean swine, as measured by lipid area on
IVPA and block chemogram on NIRS. As NIRS-IVUS lacks depth-resolution, we were
unable to characterize the source of detected lipid. These results were problematic as no
lipid-laden intimal pathology was observed on histology and NIRS spectral data is limited
to a depth of 1 mm or less [206, 254] . It is feasible that NIRS detected PVAT, given that
the artery was healthy with wall thickness less than 0.5 mm in some instances (Fig. 4.5C).
On depth-resolved IVPA-US imaging, we were able to localize the source of lipid signal
as perivascular, as confirmed by histology. Intravascular detection of PVAT would be
valuable in investigating its implication in atherogenesis. Recent studies have shown the
role of PVAT in “outside to inside” local stimulation of atherosclerotic plaque formation
via adipokines and pro-inflammatory cytokines [269]. Additionally, there is extensive
evidence of the correlation between PVAT thickness/volume and CAD metrics, such as
percent stenosis, coronary calcium score, presence of plaque, and MACE [268].
Furthermore, work by our group has shown excision of PVAT arrests atherogenesis [329,
330] . However, PVAT is traditionally measured by computed tomography along the

cardiac short axis and co-localization to intravascular measures such as plaque burden are
not possible on a routine basis. In other words, we do not have the tools necessary to answer
the question over the length of the artery: do local depots of PVAT contribute to the
development of underlying atherosclerotic lesions? This shortcoming could be addressed
by IVPA-US, which has penetration depths of up to 6 mm and can imaged plaque burden
and PVAT in one procedure.
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Notably, recent hypotheses have suggested assessment of ‘vulnerability’ not be limited
to scanning coronary arteries for solitary lesions. There is a lack of consensus evidence to
support the notion that lesions deemed high-risk by imaging are the same lesions to
progress to cardiovascular events [275, 286, 327]. In fact, many lesions regress without
event, while others rupture without event. It is proposed that lipid imaging be extended to
include assessment of the entire artery, to account for the complex and dynamic
pathophysiology regulating plaque rupture. In this work, we have shown quantification of
average cross-sectional lipid area in swine iliac arteries, without solitary lesions. The
measured difference in lipid area between groups likely arise from PVAT, a potential
mediator of atherogenesis. Thus, the demonstrated sensitivity of IVPA-US imaging for
early disease is advantageous in assessment of an entire artery for vulnerability to a future
event.
Additionally, our study provided significant findings pertinent to future clinical
application. First, we did not observe any iliac vasospasm or any other adverse
angiographic outcomes (dissection, perforation, thrombus, no-reflow) after IVPA-US
pullback. Second, no peri-procedural adverse events occurred during IVPA-US imaging,
including electrocardiograph ST-segment elevation, ventricular arrhythmias, and severe
bradycardia. Additionally, there was no apparent endothelial denudation in iliac arteries on
histology. The reported safety of our device and procedure was due to skilled operators and
the incorporation of an outer polyurethane sheath. Further testing is necessary to meet
regulatory safety and biocompatibility requirements. Lastly, clinical translation of IVPAUS will require validation against a robust data set of human histopathology, conducted ex
vivo. Here, we have shown evidence in swine demonstrating correlation between ex vivo
imaging through saline and in vivo imaging through blood. This provides strong evidence
in the methodology and results presented previously (Chapter 2 and 3), and for future ex
vivo investigations.
This study is limited by the lack of lipid-laden pathology in the iliac arteries of Ossabaw
swine and subsequent absence of analysis for correlation of in vivo lipid imaging to
histopathology. The lack of overt atherosclerosis was in spite of elevated cholesterol of
swine in the MetS group. Minimal peripheral atherosclerosis with diet alone has been
observed in this model previously [331]. In future studies, with greater catheter flexibility
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and miniaturization, we intend to advance our catheter to the swine coronary arteries in
which atherosclerotic disease develops more predictably [294, 296]. Furthermore, due to
the small sample size, we were unable to calibrate our thresholding algorithm for lipid area
to match PVAT thickness. We intend to build a larger calibration data set to address this
limitation. Lastly, in this study we used a collinear catheter design. This design, combined
with attenuation from both the sheath and luminal blood, limited US resolution.
Conclusions and Outlook
In this study, we demonstrate quantification of early atherosclerotic changes in Ossabaw
miniature swine with MetS and dyslipidemia by IVPA-US imaging, with comparison to
previously validated NIRS-IVUS imaging. We provide the first comprehensive
comparison of in vivo and ex vivo IVPA-US imaging to ex vivo NIRS-IVUS and other
existing modalities, including traditional IVUS and angiography. We detected limited lipid
content with both hybrid modalities, in agreement with mild neointimal thickening on
histology in both groups. Comparison of groups showed MetS swine had significantly
greater arterial lipid than lean swine, by both modalities. Depth resolution of IVPA-US
allowed us to localize detected lipid as PVAT.
There remain significant hurdles preventing clinical translation of IVPA-US. These
include catheter design considerations, such as further miniaturization to a 1 mm diameter
with sheath, optimized sheath material with reduced transmission loss, and broadband
transducer covering low-frequency PA signals. Furthermore, development and validation
of predictive algorithms that match IVPA-US lipid area to gold-standard histopathology
will require a considerably larger and heterogeneous sample size. Nonetheless, small
preclinical in vivo investigations performed in parallel provide unmatched feedback
towards optimal catheter design and highlight the potential opportunities for intravascular
imaging. With IVPA-US imaging, we see potential beyond imaging focal lipid-laden
plaques. Atherosclerosis is a dynamic and chronic process, with many systemic and local
factors that regulate progression to the final act: plaque rupture and thrombus. With depthresolved detection of lipids, IVPA-US is a powerful tool to delineate the role of PVAT in
this course.
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5.

CONCLUSION AND FUTURE DIRECTIONS

Conclusions
Comprehension of CAD and the complex pathophysiology leading to adverse
cardiovascular events has been in part due to the widespread development and
demonstrated utility of intravascular imaging tools over the past three decades [11, 73, 128,
161, 281, 327]. Current understanding has brought discussion and intense research to detect
‘vulnerable’ plaques or TCFAs to the front line [55, 144, 275, 276, 285, 288, 332]. It is
hypothesized that a plaque rupture contributes to approximately 1 in 10 deaths in the United
States [276, 333]. Currently, several intravascular modalities aim to target the hallmarks of
TCFAs that contribute to its propensity for dangerous rupture: a weak thin-fibrous cap with
inflammatory infiltrate, a pro-thrombogenic lipid-rich necrotic core, and positive
remodeling that evades detection on routing examination [24, 26, 55, 58, 60, 272]. Of all
technologies, NIRS-IVUS has been at the leading edge of demonstrating clinical value of
the identification of lipid core plaques as a prognostic indicator of cardiovascular
outcomes [216, 217, 221]. Preliminary studies have supported the notion that accurate
detection of vulnerable plaques by a reliable intravascular modality, or combination
of modalities, could be predictive of lesions at high risk to progress to cardiovascular
events. Multiple ongoing prospective studies using NIRS-IVUS, including
PROSPECT II ABSORB sub-study (NCT02171065), the Lipid Rich Plaque Study
(NCT02033694), PREDICT (NCT02792075), and PREVENT (NCT02316886), aim
to answer this important question [222]. Importantly, these studies must also address
interpretation of data. As NIRS-IVUS lacks depth resolution to localize and quantify
lipid cores, the threshold of risk is reliant on a LCBI metric and unclear of its meaning.
IVPA-US, an emerging modality that also targets lipids, has the power to provide
clarity in this doubt and complete a missing piece of the picture: true visualization of
lipid-rich plaque cores. This critical information—localization and quantification of
lipid within a plaque—would have substantial clinical relevance in the areas of
mechanistic studies, preventative cardiology, and interventional cardiology.
Mechanistically, in vivo ability to longitudinally monitor the dynamic changes of a
lipid core as it stabilizes or destabilizes would provide a stronger understanding of
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vulnerable plaque rupture beyond what we know from post-mortem histopathology.
Similarly, observational studies of how pharmaceutical therapies alter plaque
morphology and lipid-core size could prompt discovery of novel and aggressive
medical therapies for prevention of future cardiac events [218, 219]. Lastly, the ability
to visualize the extent to which a lipid-rich core is vulnerable to rupture based on size
and superficiality could provide a cardiologist with sufficient evidence to intervene
with a protective scaffold [277-279]. Thus, despite the numerous intravascular
imaging tools being developed or hybridized for the cardiologist’s toolbox, IVPA-US
has demonstrated powerful and unique capabilities to be at the forefront. No other
modality has the capability of chemically-specific detection of lipid with the same
resolution and depth as IVPA-US, as evidenced by the key conclusions drawn from
work presented in this dissertation.
First, we demonstrated lipid detection was feasible using an IVPA-US collinear catheter
to ex vivo image a fixed carotid artery specimen from a dyslipidemic Ossabaw swine. In a
fresh swine carotid artery with preclinical atherosclerosis, we further validated IVPA-US
with comparison against gold-standard histopathology. Additionally, we compared IVPAUS to NIRS-IVUS in this specimen, which highlighted the advantage of depth-resolved
detection and quantification. In a similar manner, we provided validation of IVPA-US
imaging for the detection of lipid core plaques in fixed and fresh human coronary artery
specimens with advanced atherosclerotic lesions. Our results were in agreement with
histopathology and NIRS-IVUS. It is only by virtue of depth-resolved lipid imaging by
IVPA, co-registered with IVUS, that we were able to localize the plaque core and calculate
total volume. Lastly, we showed in vivo feasibility using an IVPA-US catheter with an
outer sheath in a systematic comparative study performed in Ossabaw swine. Again, depth
resolution allowed us to localize lipid; however, not to a lipid-rich plaque core, but
perivascular adipose tissue. Thus, these advantages offered from the combination of light
and sound can advance our knowledge of atherosclerosis, change clinical diagnosis and
management, and ultimately reduce CAD-related morbidity and mortality.
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Future Directions
Currently, our conclusions towards validation of IVPA-US imaging for the detection,
localization, and quantification of lipid-laden atherosclerotic plaques have suffered from a
limited sample size. Naturally, the future directions of our work entail repeating described
studies with a greater sample size. Particularly, we intend to image a much larger, robust
set of post-mortem fresh human coronary arteries that include a wide range of
atherosclerotic phenotypes. An appropriate cohort would include upwards of 80 hearts and
200 total coronary artery segments, similar to landmark ex vivo studies validating OCT
[176], VH-IVUS [134], and NIRS-IVUS [203]. A subset of specimens (up to one-third)
would serve as a calibration set to develop a predictive lipid area algorithm, such that
appropriate post-processing and photoacoustic signal-to-noise thresholding would produce
quantitative imaging results that correlate to corresponding histopathology with the highest
sensitivity and specificity. For future clinical compatibility, collection of calibration data
sets should be performed in the presence of pulsatile human blood at body temperature and
pressures. The remainder would be used in a comprehensive validation set to demonstrate
predictive accuracy of IVPA-US for quantitative detection of plaque lipid in an array of
lesions. Validation studies should be double-blinded: operators performing ex vivo IVPAUS imaging and histopathology of specimens should not have access to algorithms and
vice versa. Subsequently, photoacoustic signal similarity between ex vivo and in vivo
imaging should be confirmed in preclinical and small cohort clinical investigations. It is
only after this high standard of evidence is reported that we may use IVPA-US in
prospective clinical tests to develop new conclusions about human cardiovascular disease
and test prognostic value.
It is clear clinical translation will require pathological correlation, but the overarching
aim for IVPA-US remains in vivo detection of plaques vulnerable to rupture. Our research
should be conducted in the context of providing a general clinician with a diagnostic tool
to prospectively prevent acute cardiovascular events. This means demonstration of
predictive value, not only against histopathology and outside the setting of specific imaging
expertise. Acknowledging the strengths of other modalities and integration of two or more
complementary techniques may provide the strongest opportunity towards achieving this
goal.
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APPENDIX A. IVPA-US SYSTEM ARCHITECTURE

Figure A.1. IVPA-US system architecture. Schematic of IVPA imaging system, as described in Chapter 3
and 4. OPO, optical parametric oscillator; PA, photoacoustic; US, ultrasound; PC, personal computer.
Adapted from Cao et al. (Sci Rep, 2018).

77

APPENDIX B. ANALYSIS PROTOCOLS

Figure B.1. IVUS analysis for arc of calcification. A) IVUS still-frame showing calcification from 6 to 11
o’clock, as indicated by strong echogenicity with acoustic shadowing. B) Arc of calcification, as calculated
as the maximum angle of acoustic shadowing within the total pullback length, with each ray bordering the
shadow and the vertex at the center of the vessel lumen. Example calculation shows a maximum arc of
calcification of 119o. The total length was calculated as continuous frames in which calcification was present.

Figure B.2. Histology analysis for maximal intimal thickness. A) Veorhoeff-Van Gieson stained section
from an Ossabaw swine, with inset shown in (B) magnified. B) Maximal intimal thickness was defined as
the thickest neointima (from internal elastic lamina to the lumen) at any point in the vessel. Example
calculation shows a maximal intimal thickness of 61 μm.
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APPENDIX C. PHYSIOLOGICAL BUFFER SOLUTIONS
Table C.1. EH Storage Media
Components

Concentration (mM)

1000 mL

500 mL

CaCl2

2.0

20 ml of 0.1 M

10 ml of 0.1 M

NaCl

135

135 ml of 1.0 M

67.5 ml of 1.0 M

MgCl2

1

10 ml of 0.1 M

5 ml of 0.1 M

KCl

5

50 ml of 0.1 M

25 ml of 0.1 M

KH2PO4

0.44

4.4 ml of 0.1 M

2.2 ml of 0.1 M

Na2HPO4

0.34

3.4 ml of 0.1 M

1.7 ml of 0.1 M

NaHCO3

2.6

26 ml of 0.1 M

13 ml of 0.1 M

Amino Acids

1X

20 ml of 50X

10 ml of 50X

Vitamins

1X

10 ml of 100X

5 ml of 100X

Phenol Red

0.001%

2 ml of 0.5%

1 ml of 0.5%

HEPES

20

20 ml of 1.0 M

10 ml of 1.0 M

Glucose

10

1.8 g

0.9 g

pH

7.4

with NaOH

with NaOH

PS

1%

10 ml

5 ml

Horse Serum

2%

20 ml

10 ml

EH storage medium is type of Eagle’s Minimal Essential Medium (EMEM), but also has HEPES as a pH
buffer, so that bubbling the solution with O2 is not necessary for maintenance of pH.
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